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Summary  
In 2015 WHO recommended antiretroviral treatment (ART) for all HIV-positive individuals 
regardless of CD4 count and set a target for Universal Access to ART, that >80% of HIV-
positive individuals should be on ART. The HPTN 071 (PopART) trial, a community 
randomized trial in 21 communities in South Africa and Zambia, aims to to determine the 
impact of two community-level combination prevention packages on population-level HIV 
incidence. HPTN 071 (PopART) has implemented household-based HIV point of care testing 
(POCT) and provided ART regardless of CD4 count at department of health clinics (DOH) in 
the trial communities from January 2014. This was ahead of recent changes to WHO and 
South African ART guidelines, which now provide ART regardless of CD4 count. The primary 
outcome of HIV incidence was evaluated in a randomly selected research cohort, the 
Population Cohort (PC), which aims to recruit 44,500 HIV-positive and negative participants 
aged 18 to 45, approximately 2000 from each of the 21 communities.  
 
The aim of this PhD dissertation was to evaluate the outcomes of clinical activities key to 
effective provision of HIV treatment services in high burden settings. PhD objectives were to 
evaluate: i) the accuracy of household HIV POCT and the impact of routine initiation of ART 
at baseline CD4 counts > 500cells/mL on ii) attrition during early ART, iii) TB incidence during 
early ART, iv) the incidence of renal dysfunction during early ART and iv) adherence to ART.  
These objectives were addressed through the completion of five studies.  
 
Four of the five studies presented were embedded within the HPTN 071 (PopART) trial. The 
fifth study, evaluating ART adherence, was a systematic review and meta-analysis. The study 
presented in chapter 3, evaluated the accuracy of household-based HIV POCT between 
January 2014 and August 2016 across all 21 PopART sites in both South Africa and Zambia, 
through a series of cross-sectional analyses.  This study showed initial low HIV POCT 
sensitivity in South Africa (45-54%). HIV POCT sensitivity in Zambia, which implemented 
more extensive quality assurance (QA) and quality control (QC) and used different HIV POCT 
kits, during the same time period, was significantly better (95.8%). HIV POCT sensitivity in 
South Africa improved over time to rates comparable to the Zambian sites when 
implementing rigorous HIV POCT QA/QC.  
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The studies presented in chapters 4 to 6 analysed data on a cohort of adults (≥18years of 
age) initiating ART regardless CD4 count at three department of health (DOH) clinics in the 
Western Cape, South Africa; between January 2014 and November 2015. Cohort follow-up 
was completed at the end of May 2016. The cohort studies evaluated the impact of routine 
initiation of ART at baseline CD4 counts >500 cells/µL on i) attrition ii) TB incidence and ii) 
incidence of renal dysfunction during early ART.  
 
A total of 2423 adults with a median baseline CD4 count of 328 (IQR 195-468) cells/µL were 
included in the clinic cohort. Attrition included individuals no longer retained in ART care 
due to loss to follow up or death (chapter 4). A total of 636 (26.2%) adults in the cohort 
experienced attrition during the follow-up period. Attrition was higher amongst individuals 
with baseline CD4 counts >500 cells/µL compared to individuals with baseline CD4 counts 0-
500 cells/µL (aHR 1.28, 95%CI 1.07 -1.55). This finding raised concerns about the potential 
for increased attrition from ART care when providing ART regardless of CD4 count.  
 
The overall TB incidence in the cohort was 4.4 cases/100PY (chapter 5). TB incidence was 
lower amongst individuals with baseline CD4 counts >500 cells/µL compared to those with 
baseline CD4 counts 0-500 cells/ µL (aHR=0.27; 95% CI 0.12 to 0.62). There were no incident 
TB cases in the first three months of ART amongst individuals with baseline CD4 counts > 
500 cells/ µL. These findings were promising, highly suggestive that routine provision of ART 
at baseline CD4 counts >500 cells/µL will lead to a significant reduction in TB amongst 
individuals starting ART.  
 
 The prevalence of baseline moderate or severe renal dysfunction (Estimated Glomerular 
Filtration Rate (EGFR) < 60ml/min) in the cohort was low (1.9%) (chapter 6), as was the rate 
of incident moderate or severe renal dysfunction after initiation of ART (1.9cases/100PY).  
The study showed no significant association between baseline CD4 count and incident 
moderate or severe renal dysfunction occurring after initiation of ART. Analysis restricted to 
individuals with normal baseline renal function, showed no cases of incident moderate or 
severe renal dysfunction amongst individuals with baseline CD4 counts >500cells/ µL. This is 
also a promising finding that needs to be confirmed by completion of further studies.  
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The fifth study (chapter 7), was a systematic review and meta-analysis of studies published 
between 2004 and 2015, which evaluated the association between baseline CD4 count and 
ART adherence. This systematic review showed lower ART adherence amongst individuals 
starting ART at higher baseline CD4 counts categories (pooled OR 0.90; 95%CI 0.84-0.96).  
Baseline CD4 count categories used in the included studies varied. The most commonly used 
comparison was between individuals initiating ART at CD4 counts > 200 cells/µL and at CD4 
counts 0-200 cells/µL. In the two included studies that reported on individuals with baseline 
CD4 counts > 500 cells/µL, there was no difference in ART adherence between individuals 
with baseline CD4 counts > 500 cells/µL and those with baseline CD4 counts 0-500 cells/µL. 
 
Overall the studies presented for this PhD dissertation demonstrated both benefits and 
challenges when conducting household-based HIV POCT and routinely initiating ART in HIV-
positive individuals at baseline CD4 counts >500cells/µL. The studies presented in chapters 5 
and 6 suggest potential reduction in incidence of TB and renal dysfunction with routine 
provision of ART at baseline CD4 counts >500cell/µL; providing a strong motivation for 
striving to attain universal access to ART in high burden settings.   At the same time, the 
reported low HIV POCT sensitivity and the need for rigorous QA/QC when implementing 
household-based HIV POCT was concerning. As were the study findings showing higher 
attrition and poorer ART adherence when initiating ART at higher CD4 counts. Strategies to 
improve HIV POCT sensitivity, retention in ART care and ART adherence, in these contexts, 
should therefore be a priority for programme implementers in high-burden settings.   
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Opsomming  
Die Wêreldgesondheidsorganisasie (WGO) het in 2015 antiretrovirale behandeling (ART) 
aanbeveel vir alle MIV-positiewe individue, ongeag hulle CD4-telling. Wat universele 
toegang tot ART betref, het die WGO die mikpunt gestel dat ten minste 80% van MIV-
positiewe individue op ART behoort te wees. Die doel van die HPTN 071 (PopART) proef, ’n 
verewekansigde proef in 21 gemeenskappe in Suid-Afrika en Zambië, is om te bepaal hoe 
twee kombinasievoorkomingspakkette op gemeenskapsvlak MIV-insidensie op 
bevolkingsvlak beïnvloed. HPTN 071 (PopART) het sedert Januarie 2014 tuisgebaseerde MIV-
sorgpunttoetsing (“POCT”) van stapel gestuur en, ongeag CD4-telling, ART by staatsklinieke 
in die proefgemeenskappe voorsien. Dít was vóór die onlangse veranderinge aan WGO- en 
Suid-Afrikaanse riglyne oor ART, wat nou vir ART-behandeling ongeag CD4-telling 
voorsiening maak. Die hoofuitkoms van MIV-insidensie is beoordeel in ’n ewekansig-gekose 
navorsingskohort, die populasiekohort (“PC”), wat beoog om uiteindelik 44 500 MIV-
positiewe en -negatiewe deelnemers tussen die ouderdom van 18 en 45 – sowat 2 000 uit 
elk van die 21 gemeenskappe – te werf.  
 
Die doel van hierdie PhD-proefskrif was om die uitkomste te bepaal van kliniese aktiwiteite 
wat die kern uitmaak van die doeltreffende voorsiening van MIV-behandelingsdienste in 
omgewings met ’n hoë siektelas. Die doelwitte van die PhD-studie was om te evalueer i) hoe 
akkuraat tuisgebaseerde MIV POCT is en watter impak die roetineaanvang van ART by 
individue met CD4-basislyntellings bo 500 selle/µL het op ii) attrisie in die vroeë fases van 
ARV-behandeling, iii) TB-insidensie in die vroeë fases van ARV-behandeling, iv) die insidensie 
van nierdisfunksie in die vroeë fases van ARV-behandeling, en v) ARV-getrouheid. In die 
strewe na hierdie doelwitte is vyf studies uitgevoer.  
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Vier van die vyf studies is binne die HPTN 071 (PopART) proef uitgevoer. Die vyfde studie, 
wat ARV-getrouheid beoordeel, was ’n stelselmatige oorsig en metaontleding. Die studie 
wat in hoofstuk 3 beskryf word, het ’n aantal deursneeontledings gebruik om die 
akkuraatheid van tuisgebaseerde MIV POCT tussen Januarie 2014 en Augustus 2016 by ál 21 
PopART-terreine in Suid-Afrika sowel as Zambië te beoordeel. Hierdie studie het op 
aanvanklik lae MIV POCT-sensitiwiteit in Suid-Afrika gedui (45-54%). MIV POCT-sensitiwiteit 
in Zambië, wat meer omvattende gehalteversekering en -beheer toegepas en ander MIV 
POCT-toestelle gebruik het, was beduidend beter vir dieselfde tydperk (95,8%). MIV POCT-
sensitiwiteit in Suid-Afrika het mettertyd verbeter tot soortgelyke syfers as in Zambië deur 
die toepassing van streng gehalteversekering en -beheer.  
 
Die studies wat in hoofstuk 4 tot 6 gemeld word, het die data ontleed van ’n kohort 
volwassenes (18 jaar of ouer) wat tussen Januarie 2014 en November 2015 by drie 
staatsklinieke in die Wes-Kaap, Suid-Afrika, met ART begin het. Kohortnasorg is teen die 
einde van Mei 2016 voltooi. Die kohortstudies het bepaal watter impak die roetineaanvang 
van ART by individue met CD4-basislyntellings bo 500 selle/µL het op i) attrisie, ii) TB-
insidensie, en iii) die insidensie van nierdisfunksie in die vroeë fases van ARV-behandeling.  
 
Altesaam 2 423 volwassenes met ’n gemiddelde CD4-basislyntelling van 328 (IQR 195-
468) selle/µL is by die kliniekkohort ingesluit. Attrisie het individue ingesluit wat verlore was 
vir ARV-sorg weens hetsy verlies uit die nasorgstelsel of sterfte (hoofstuk 4). ’n Totaal 
van 636 (26,2%) volwassenes in die kohort het in die loop van die nasorgtydperk attrisie 
ervaar. Attrisie was hoër onder individue met CD4-basislyntellings bo 500 selle/µL vergeleke 
met diegene met CD4-basislyntellings van 0-500 selle/µL (aHR 1,28, 95% CI 1,07-1,55). 
Hierdie bevinding wek kommer oor ’n moontlike toename in attrisie uit ARV-sorg wanneer 
ART ongeag CD4-tellings voorsien sal word.  
 
Die algehele TB-insidensie in die kohort was 4,4 gevalle/100 PJ (hoofstuk 5). TB-insidensie 
was laer onder individue met CD4-basislyntellings bo 500 selle/µL vergeleke met diegene 
met CD4-basislyntellings van 0-500 selle/µL (aHR = 0,27; 95% CI 0,12-0,62). Daar was geen 
voortvloeiende TB-gevalle in die eerste drie maande van ARV-behandeling onder individue 
met CD4-basislyntellings bo 500 selle/µL nie. Hierdie bevindinge is belowend en ’n sterk 
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aanduiding dat die roetinevoorsiening van ART op CD4-basislyntellings bo 500 selle/µL tot ’n 
beduidende afname in TB sal lei onder individue wat met ARV-behandeling begin.  
 
Die prevalensie van matige of ernstige basislynnierdisfunksie (geskatte glomerulêre 
filtreertempo (“EGFR”) van minder as 60 ml/min) in die kohort was laag (1,9%) (hoofstuk 6), 
en so ook die insidensiesyfer van matige of ernstige nierdisfunksie ná die aanvang van ART 
(1,9 gevalle/100 PJ). Die studie dui op geen beduidende verband tussen CD4-basislyntellings 
en voortvloeiende matige of ernstige nierdisfunksie ná die aanvang van ARV-behandeling 
nie. Ontleding van slegs daardie individue met normale basislynnierfunksie bring geen 
gevalle van voortvloeiende matige of ernstige nierdisfunksie aan die lig onder diegene met 
CD4-basislyntellings bo 500 selle/µL nie. Ook dít is ’n belowende bevinding, wat met verdere 
studies bevestig moet word.  
 
Die vyfde studie (hoofstuk 7) was ’n stelselmatige oorsig en metaontleding van studies wat 
tussen 2004 en 2015 gepubliseer is en wat die verband tussen CD4-basislyntellings en ARV-
getrouheid beoordeel. Hierdie stelselmatige oorsig dui op laer ARV-getrouheid onder 
individue wat in hoër CD4-basislyntellingkategorieë met ARV-behandeling begin 
(saamgevoeg OF 0,90; 95% CI 0,84-0,96). Voormelde gepubliseerde studies het van 
verskillende CD4-basislyntellingkategorieë gebruik gemaak. Die algemeenste vergelyking 
was dié tussen individue wat op CD4-tellings bo 200 selle/µL en CD4-tellings van 0-
200 selle/µL met ARV-behandeling begin. In die twee gepubliseerde studies wat oor 
individue met CD4-basislyntellings bo 500 selle/µL verslag gedoen het, was daar geen verskil 
in ARV-getrouheid tussen individue met CD4-basislyntellings bo 500 selle/µL en dié met 
CD4-basislyntellings van 0-500 selle/µL nie. 
 
Die studies wat vir hierdie PhD-proefskrif onderneem is, bring oor die algemeen bepaalde 
voordele sowel as uitdagings aan die lig wat tuisgebaseerde MIV POCT en die roetine 
voorsiening van ART by MIV-positiewe individue met CD4-basislyntellings bo 500 selle/µL 
betref. Die studies in hoofstukke 5 en 6 dui op ’n moontlike afname in die insidensie van TB 
en nierdisfunksie met die roetine voorsiening van ART op CD4-basislyntellings bo 500 
selle/µL, wat as sterk motivering dien vir die strewe na universele toegang tot ART in 
omgewings met ’n hoë siektelas. Terselfdertyd is die aangemelde lae MIV POCT-sensitiwiteit 
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en die behoefte aan streng gehalteversekering en -beheer in die implementering van 
tuisgebaseerde MIV POCT kommerwekkend, soos ook die bevindinge wat dui op hoër 
attrisie en swakker ARV-getrouheid onder diegene wat op hoër CD4-tellings met ARV-
behandeling begin. Strategieë om MIV POCT-sensitiwiteit, behoud in ARV-sorg sowel as 
ARV-getrouheid in hierdie konteks te verbeter, behoort dus ’n voorrangsaak te wees vir 
program implementeerders in omgewings met ’n hoë siektelas.   
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Chapter 1: Introduction  
This PhD dissertation evaluated clinical outcomes key to achieving universal access to 
antiretroviral treatment (ART) in settings with an human immune deficiency virus (HIV) 
prevalence rate ≥1% (high-burden settings). (1) The introductory chapter describes the 
burden of HIV, pathogenesis of HIV infection, approaches to ART and the effectiveness of 
ART in reducing morbidity and mortality in HIV-positive individuals in high-burden settings. 
This chapter also provides an overview of the methodology and layout of the dissertation 
and how the research objectives address existing gaps in the research evidence for best 
practice in implementation of HIV treatment services in high-burden settings.  
 
1.1 HIV burden of disease 
More than 30 years after the HIV virus was first identified, (2) there remains no effective 
preventative vaccine or cure and the illness continues to affect millions of individuals. In 
2016, there were an estimated 36.7 million HIV-positive individuals and a million HIV-related 
deaths globally, with an HIV prevalence rate in 18 to 45 year olds of 0.8%. (3) The burden of 
HIV is heavily focused in poorer developing regions. In 2016 there were 19.4 million HIV-
positive individuals, more than half the global total, living in Eastern and Southern Africa. (3) 
In the same year there were 420 000 HIV-related deaths in the region, with an HIV 
prevalence amongst 18 to 45 year olds of 7.0%. (3) In Zambia, in 2016, there were a 
reported 1.2 million HIV-positive individuals and 21 000 HIV-related deaths, with an HIV 
prevalence amongst 18 to 45 year olds of 12.4%. (3) South Africa has one of the largest HIV-
positive populations globally, with 6.9–7.03 million HIV-positive individuals, and a high 
number of HIV-related deaths (110 000) in 2016. This massive burden of HIV in South Africa 
is emphasised by the HIV prevalence rate amongst 18 to 45 year olds of 18.9%, as estimated 
by UNAIDS, in 2016. (3, 4) This HIV prevalence rate is higher than that reported by Statistics 
South Africa for 2015 (16.6%), (3, 4) and very similar to that reported by the Human 
Sciences Research Council (HSRC) Survey for 2012 (18.8%) for the same age group. (5) The 
HSRC also reported wide variation in HIV prevalence in 18 to 45 year olds across South 
Africa, ranging from 7.8% in the Western Cape to 27.9% in KwaZulu-Natal. (5) 
1.2 HIV pathogenesis 
HIV is transmitted through exposure of mucosal surfaces to infected body fluids, including 
blood, semen, vaginal fluids, rectal fluids and breast milk. (6) Transmission occurs typically 
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during sexual intercourse, by percutaneous inoculation as in a needle-stick injury, needle-
sharing by intravenous drug users or by transmission from mother to child during 
pregnancy, childbirth and breast-feeding. (6) There are two main HIV strains, HIV 1 and HIV 
2, which are similar with respect to genetic structure, modes of transmission and replication 
within cells. HIV 2, however, shows lower transmissibility and rates of progression to 
acquired immune deficiency syndrome (AIDS) and is more resistant to some antiretrovirals 
commonly used in high-burden settings. HIV 1 is responsible for the vast majority of HIV 
infections worldwide, with HIV 2 infection largely restricted to West Africa. (7, 8) 
 
Once the HIV virus is introduced into an individual’s bloodstream, the typical sequence of 
infection includes the following steps (9):  
i) HIV in the bloodstream enters T lymphocyte cells by way of the CD4 and either 
CC-chemokine 5 (CCR5) or CXC chemokine receptor 4 (CXCR4) through 
interaction with envelope (Env) glycoprotein;  
ii) after fusion and un-coating within the cell, the viral RNA is reverse transcribed 
into DNA by the  action of the reverse transcriptase enzyme; 
iii) integration of viral DNA into host DNA within the lymphocyte through the action 
of the viral enzyme integrase. This integrated viral DNA is called ‘pro virus’;  
iv) transcription of pro virus into multiple RNA copies through cleavage of DNA 
polypeptide sequences by viral protease enzyme activation to produce new viral 
RNA; 
v) assembly and budding and release from the lymphocyte of viral RNA into the 
bloodstream where it may infect other lymphocytes. 
 
The natural course of untreated HIV infection is increasing serum viral load, with an 
associated decline in T lymphocytes exhibiting the CD4 antigen (CD4 cells) leading to 
immunosuppression. (10, 11) Stages in the progression of HIV infection to AIDS include:  
i) primary infection, during which the HIV RNA is present at very high levels in the 
host bloodstream; however, HIV antibodies are not yet detectable. The high 
serum viral load during this period is associated with high risk of development of 
viral reservoirs, where CD4 cells, in areas such as the brain and lymphoid tissue, 
are infected with replicable HIV virus. The high rates of viral load during this 
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period are also associated with increased risk of onward transmission of HIV; 
(12, 13) ii) seroconversion, with the development of a host antibody response;  
iii) progression through a period of absence of clinical symptoms or limited 
symptoms; and  
iv) decline in CD4 cells and occurrence of AIDS, a symptom-based diagnosis made 
on occurrence of opportunistic infections or HIV-related cancers. (10, 14)  
 
The WHO has developed clinical criteria for the staging of AIDs, with stages 1 to 4 based on 
the diagnosis of HIV-related illnesses. (14)  
 
1.3 HIV diagnosis  
Diagnosis of HIV in high-burden setting is primarily completed using HIV point of care tests 
that measure HIV serum antibodies on whole blood obtained through finger pricking.  
Sequential with confirmation of the HIV status amongst individuals testing HIV positive on 
the first HIV POCT by a second HIV POCT using a different test kit is recommended as 
standard care for high-burden settings. (15) Provision of HIV testing services at both clinic 
and community, including household settings is recommended and there has been a steady 
expansion of community based HTS over the last decade. (15) Sensitivity of commonly used 
HIV POCT kits is high in controlled laboratory settings (>98%); (16) however there are limited 
high quality data from field settings (both community and clinic) and available data show 
varying sensitivity in these contexts. Effective scale up of HTS in high-burden settings is 
challenged by poor uptake amongst high risk population groups and commonly reported. 
HIV POCT false negative and HIV false positive results in both clinic and community settings. 
(15) 
 
1.4 Mechanisms of action of antiretrovirals 
ART inhibits viral replication with associated decline in serum viral load and increase in CD4 
cell count. (9) (17)ART drugs commonly used in high-burden settings inhibit HIV reverse 
transcriptase enzyme and can be categorised primarily in two groups: non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors 
(NRTIs). Based on available evidence from randomised controlled trials (RCTs) and 
programmatic studies, the WHO recommends a limited number of first-line ART regimens 
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for adult treatment in high-burden settings which commonly include two NRTIs, tenofovir 
(TDF) plus lamivudine (3TC) or emtricitabine (FTC) and an NNRTI, such as efavirenz (EFV) or 
nevirapine (NVP). (18) A fixed-dose combination of TDF, 3TC/FTC and EFV remains the  
preferred first-line option in many high-burden settings. Use of protease enzyme inhibitors 
and integrase enzyme inhibitors in high-burden settings is largely restricted to second- and 
third-line treatment. (18) 
 
Routine viral load monitoring is recommended for high-burden settings and is implemented 
in selected countries such as South Africa. (18) Continued viral replication, while individuals 
are on ART, can promote the selection of HIV virus with drug-resistant mutations (DRMs) 
during viral replication. Drug-resistant HIV virus can then be transmitted to other 
individuals, limiting ART effectiveness. The number of DRMs required to cause resistance 
varies between different ART drugs. (19) In response to increasing rates of HIV drug 
resistance (HIVDR), particularly to NNRTIs, there is a push toward strengthening HIVDR 
monitoring in high-burden settings through completion of sentinel HIVDR surveys. (18) In 
contrast, individuals starting ART in more developed countries, such as the United States, 
have routine access to individualised genotypic screening for HIVDR, the results of which are 
used to inform the choice of first-line ART; this may include a wider range of first-line ART 
drugs, including protease inhibitors (PIs), ritonavir-boosted PIs and integrase inhibitors such 
as dolutegravir (DTG), which are less susceptible to HIVDR. (20, 21) 
 
1.5 HIV treatment coverage in high-burden settings 
In 2014, UNAIDS published the 90-90-90 targets: that by the end of 2020, 90% of people 
living with HIV know their HIV status; 90% of individuals diagnosed with HIV are on ART; and 
90% of individuals on ART are virally suppressed. (22) In addition, in 2016, the WHO 
recommended ‘Universal Access to ART’, defined as >80% of HIV-positive individuals on 
ART. (18) Responding to the need for rapid scale-up of HIV treatment services required to 
achieve these targets, (3, 18, 22) while maintaining quality of care in high-burden settings, is 
extremely challenging, (23) with poor uptake at all stages of the HIV treatment cascade, 
namely, HIV diagnosis, linkage to care, ART uptake, retention on ART and viral load 
suppression. (3, 18, 22) 
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Strengthening community-based HIV testing service (HTS) strategies is critical to increasing 
HTS coverage. (15, 18) Published studies show community-based HTS to be highly 
acceptable and effective in identifying HIV-positive individuals in high-burden settings, 
including certain high-risk groups such as men. (24-26) Good progress has been made over 
recent years in increasing HTS coverage, with an estimated 76% of HIV-positive individuals 
in Eastern and Southern Africa and 86% in South Africa knowing their HIV status; however, 
challenges in delivery of HTS remain. (3) In addition to low HTS coverage in many high-
burden settings, there is concern over accuracy of HIV point of care (POCT) kits, commonly 
used in high-burden settings. These kits  measure HIV antibodies in whole blood attained by 
finger prick, (15) and show decreased sensitivity during HIV seroconversion and in advanced 
HIV disease when positive individuals may be antigen-positive with low antibody titres. (27-
29)  
 
There are also challenges with linkage to ART care and ART initiation after HIV diagnosis. 
Overall rates of linkage to ART care are low compared to global targets, with only 60% of 
HIV-positive individuals in Eastern and Southern Africa and 56% of HIV-positive individuals in 
South Africa who know their HIV status on ART (3). Delays in the time between HIV 
diagnosis and ART initiation are also common, and delay in initiation of ART is further 
exacerbated by high rates of loss to follow-up from clinic care prior to ART initiation (pre-
ART care). (24, 30)  
 
After ART initiation, there are high rates of attrition from ART care and non-adherence to 
ART amongst individuals remaining in care, both of which are associated with increased viral 
load and increased rates of HIVDR. (31-33) To illustrate, a recent systematic review reported 
40% attrition from ART care (defined as no longer retained in ART care due to loss to follow-
up or death) in sub-Saharan African (SSA) countries after 24 months ART duration. (34) 
There is also a worrying trend toward deteriorating clinical outcomes as health facilities 
become overburdened by increasing numbers of ART patients, (35, 36) as well as concerns 
about low rates of viral load suppression and increasing rates of HIVDR amongst individuals 
retained in ART care. A multi-centre programmatic study from Africa showed variable HIV 
viral suppression during the first 24 months of ART, ranging from 2.6 to 20.6%, with high 
levels of HIVDR. (37) Although viral load monitoring is recommended in all settings, it is not 
routinely provided in many high-burden settings, due to lack of the necessary laboratory 
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infrastructure. (38) In settings where viral load monitoring is available, there are reports of 
poor implementation, (38) with <60% of scheduled viral load tests completed, as per ART 
guidelines, at PHC clinics in the Western Cape. (39) 
 
ART adherence is defined as the extent to which an individual’s taking of prescribed 
medication corresponds with healthcare provider recommendations. (1) Poor ART 
adherence is strongly associated with increased viral load and development of HIVDR 
amongst HIV-positive individuals on ART. (31, 40, 41) ART adherence support is extremely 
challenging in busy primary healthcare (PHC) clinics, and there is marked heterogeneity in 
methodologies used for promoting and monitoring adherence between programmes. (42, 
43) A systematic review of published studies from Africa, showed overall poor ART 
adherence, with study participants taking <60% of prescribed ART drugs. (44) In this context, 
there is growing concern about HIVDR in high-burden settings. National HIVDR surveillance 
estimates in high-burden settings showed that in six out of ten countries surveyed, more 
than 10% of individuals initiating ART had NNRTI resistance, with increased HIVDR among 
individuals with previous ART exposure. (33) In response to these findings, the WHO has 
published recommendations for management of pre-ART HIVDR. (41) These 
recommendations included substitution of EFV and NVP in first-line ART regimens with DTG 
or ritonavir-boosted PIs; however, these new guidelines are not fully implemented in high-
burden settings. (41) 
 
1.6 Morbidity and mortality in HIV-positive individuals 
AIDs-related mortality is defined as mortality as the result of an HIV-related illness (HIV-
related morbidity). (45) In countries in high-burden settings, including Zambia and South 
Africa, AIDS-related mortality caused by HIV-related illnesses continue to be the most 
common cause of mortality amongst HIV-positive individuals. (46, 47)  This is in contrast to 
more developed countries, such as the United States, where non-HIV-related illnesses, 
including cardiovascular disease and non-AIDS-defining cancers, are increasingly common. 
(47) 
 
In 2015, there was an estimated annual TB incidence of 142/100 000 population and 
195/100 000 population globally and in high-burden settings, respectively. (48) In the same 
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year, South Africa had the highest estimated annual TB incidence worldwide (834/100 000 
population), with 57% of TB cases occurring in individuals co-infected with HIV. (48) TB in 
HIV-positive individuals initiating ART is more common amongst those with lower CD4 cell 
counts at the time of ART initiation (baseline CD4 count). A study from Cape Town, South 
Africa, reported TB incidence rates among HIV-positive individuals starting ART that ranged 
from 25 cases/100 person years at baseline CD4 counts <100 cells/µL to five cases/100 
person years at baseline CD4 counts >350 cells/µL. The study had limited data on individuals 
with baseline CD4 counts >500cell/µL. (49) Amongst HIV-positive individuals initiated on 
ART, published data show higher TB incidence during the first four months of ART and 
approximately double in the first year of ART compared to subsequent years. (50-53). These 
increased TB incidence rates during initial months on ART may, in part, be attributable to 
restored immune response in individuals initiated on ART, leading to immune reconstitution 
inflammatory syndrome (IRIS) with clinical presentation of previously asymptomatic TB. (51)  
 
Renal dysfunction occurs through a variety of mechanisms, including HIV-related 
nephropathy (HIVAN), HIV immune complex kidney disease, thrombotic microangiopathy 
and toxicity to some ART drugs such as tenofovir. (54, 55) Routine monitoring of renal 
function through measurement of serum estimated glomerular filtration rate (EGFR) is 
recommended for individuals started on tenofovir-containing regimens. (18, 56) American 
National Kidney Foundation recommendations for the classification of renal dysfunction are 
based on serum EGFR as follows; mild renal dysfunction (EGFR 60 - 89 mL/min), moderate 
renal dysfunction (EGFR 30 - 59 mL/min) or severe renal dysfunction (EGFR <30mL/min). 
(57)  
 
Renal dysfunction is a common HIV-related illness, diagnosed in approximately 20% of HIV-
positive individuals initiating ART in South Africa, (58) and is associated with increased 
mortality amongst individuals initiating ART. (59) The reported association between baseline 
CD4 count and baseline renal dysfunction varies, with some studies showing higher baseline 
renal dysfunction at lower CD4 counts, (59, 60) and other studies showing no association. 
(58, 61) Programmatic studies, with median baseline CD4 counts ranging from 154 to 209 
cells/µL, show decreased renal dysfunction after ART initiation amongst individuals with 
baseline CD4 counts >200 cells/µL compared to lower values. (62, 63) With respect to the 
impact of initiating ART at baseline CD4 counts >500 cells/µL, results from a recently 
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published randomised control trial (RCT) showed higher average EGFR after ART initiation 
amongst individuals starting ART at baseline CD4 counts >500 cells/µL when compared to 
those with baseline CD4 350 to 500 cells/µL. (64). 
 
1.7 ART impact on morbidity and mortality in HIV-positive individuals 
Published data from programmatic cohorts and RCTs clearly demonstrate the effectiveness 
of ART in reducing the occurrence of HIV-related illnesses (AIDS-related morbidity) and all-
cause mortality in HIV-positive individuals when initiating ART at baseline CD4 counts <200 
cells/µL. [16-18] Published data also show further reductions in AIDS-related morbidity and 
all-cause mortality when initiating ART at baseline CD4 counts 200 to 350 cells/µL compared 
to baseline CD4 counts <200 cells/µL. Further reductions are seen when initiating ART at 
baseline CD4 counts 351 to 500 cells/µL when compared to initiating ART at baseline CD4 
counts <350 cells/µL. [19, 20] 
Two recent RCTs that describe the impact of ART started at CD4 counts >500 cells/µL have 
greatly influenced debate on when to routinely start ART: The Early Antiretroviral Treatment 
and/or Early Isoniazid Prophylaxis against Tuberculosis in HIV-positive Adults (ANRS 12136 
TEMPRANO) and the Strategic Timing of Antiretroviral Treatment (START) trials. [21, 22] 
TEMPRANO showed a 44% reduction in severe AIDS-related morbidity, including TB and all-
cause mortality, when ART was initiated at baseline CD4 counts 500 to 800 cells/µL, 
compared to cases when ART was started according to pertinent ART guidelines, which 
changed, in the trial sites, from a CD4 cut-off for ART initiation from 350 cells/µL to 500 
cells/µL part way through the trial. [21] In addition, the trial showed a 35% reduction in 
severe morbidity when six months isoniazid (INH) prophylaxis (IPT) was added at the start of 
ART. [21] Results from the START trial, first released in May 2015, supported these findings, 
showing a 57% reduction in a composite primary end point of any serious AIDS-related 
event or serious non-AIDS-related event or death from any cause amongst participants 
starting ART at CD4 counts>500 cells/µL, compared to between 351 and 500 cells/µL. [22] 
START also showed a reduction in occurrence of specific diseases in the intervention arm, 
including TB and renal dysfunction. (64, 65)  
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1.8 ART access in HIV high-burden settings 
There has been a steady broadening in eligibility criteria for access to ART in high-burden 
settings since 2002. The first WHO ART guidelines for high-burden settings, published in 
2002, used a CD4 cut-off of 200 cells/µL for ART initiation. (66) In 2010, the CD4 cut-off was 
changed from 200 to 350 cells/µL, (67) and in 2013 from 350 cells/µL to 500 cells/µL. (1) 
Further updated WHO HIV treatment guidelines, first published in 2015, (11) based primarily 
on the results of the TEMPRANO and START trials, recommended ART for all HIV-positive 
individuals regardless of CD4 count. ART access criteria in South Africa, including in the 
Western Cape Province, have changed in line with WHO recommendations. In January 2015, 
South African and Western Cape ART guidelines changed the CD4 cut-off for ART from 350 
to 500 cells/µL, (68) and in October 2016 ART guidelines changed to recommending ART 
regardless of CD4 count. (69)  
 
1.9 Gaps in research evidence for HIV treatment  
RCTs, such as TEMPRANO and START, remain the gold standard for clinical evidence, with 
random allocation of individuals to treatment and comparison arms, along with accurate 
standardisation of interventions and outcome measurements. (70) However, given that 
RCTs are undertaken under rigid research conditions, which often do not reflect real-life 
programmatic conditions, there is also a need for data from operational research studies, 
defined as studies completed in programmatic settings, (71) when developing clinical 
guidelines. (71) There are good data from both RCTs and operational research studies of 
additional reductions in HIV-related morbidity and all-cause mortality as a result of initiation 
of ART at higher baseline CD4 counts, up to baseline CD4 counts ≤500 cells/µL. However, 
there remains a dearth of data from high-burden programmatic settings evaluating the 
impact on HIV-related morbidity and all-cause mortality of routine initiation of ART at CD4 
counts >500 cells/µL. 
 
In this context, the overall aim of this PhD dissertation was to evaluate the accuracy of 
household HIV testing and the impact of routine provision of ART >500 cells/µL in HIV-
positive adults on rates of attrition from ART care, on TB incidence and on renal dysfunction. 
In addition, a systematic review of published literature evaluating the association between 
baseline CD4 count and ART adherence was conducted.  
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1.10 PhD dissertation outline  
1.10.1 PhD dissertation context 
The original studies in this PhD dissertation research were embedded within the HPTN 071 
(PopART) trial in South Africa. The HPTN 071/Population Effects of Antiretroviral Therapy to 
Reduce HIV Transmission (PopART) trial is a community randomised trial currently in 21 
communities in South Africa and Zambia. PopART field activities began in January 2014 and 
are scheduled to be completed in June 2018. The aim of the trial is to determine the impact 
of two community-level combination prevention packages on population-level HIV incidence. 
(72) PopART communities were randomly allocated to Arms A, B or C. The PopART household 
intervention was delivered to all individuals in Arm A and B communities by a cadre of 
community HIV care providers (CHiPs). DOH clinics in communities allocated to Arm A 
provided ART regardless of CD4 count from January 2014, 18 to 24 months ahead of recent 
changes to South African and Western Cape ART guidelines. (68) Clinics allocated to Arms B 
and C provided ART as per local standard care. (11, 68) The primary outcome of HIV incidence 
is evaluated in a randomly selected research cohort, the Population Cohort (PC), which aims 
to recruit 52,500 HIV-positive and negative participants aged 18 to 45, 2500 from each of the 
21 communities. A full description of the PopART trial is provided in chapter 2.  
 
1.10.2 PhD aim and objectives  
Overall PhD aim 
The aim of this PhD dissertation was to evaluate the outcomes of clinical activities key to 
effective provision of HIV treatment services in high-burden settings.  
PhD objectives  
To evaluate within the PopART PC 
1. The accuracy of household HIV POCT  
To evaluate the impact of routine initiation of ART at baseline CD4 counts >500cells/µL at 
DOH ART clinics on  
2. Attrition during early ART 
3. TB incidence during early ART 
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4. The incidence of renal dysfunction during early ART 
To evaluate through completion of a systematic review and meta-analysis of published 
literature:  
5. The association between baseline CD4 count and adherence to ART.   
 
1.10.3 Overview of PhD dissertation chapters  
In chapter 2, I give a brief summary of the outline of the HPTN 071/ Population Effects of 
Antiretroviral Therapy to Reduce HIV Transmission (PopART) trial in which the work for this 
thesis is embedded.  
 
Chapters 3 to 7 present the studies completed for this PhD. In each chapter the study is 
prefaced by an introduction that provides: i) the citation for the study presented in the 
chapter where relevant. ii) a brief overview of the study design and how the study was 
positioned with the PopART trial iii) an outline of which data were used for the completion 
of the study and iv) an outline of my contribution and the contribution of the co-authors to 
the completion of the study presented in the chapter.  
 
The study presented in chapter 3, ‘Understanding low sensitivity of community-based HIV 
rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South 
Africa’,evaluated the accuracy of household-based HIV POCT. In addition, I present the 
activities we put in place to improve the accuracy and the lessons that can be learnt from 
this for the roll-out of community-based HIV POCT.  
 
For the work presented in chapters 4-6, I set up a cohort of HIV-positive individuals who 
initiated ART regardless of CD4 count at DOH clinics. This cohort offered the opportunity to 
evaluate clinical outcomes during the routine provision of ART regardless CD4 count in HIV 
positive adults and provide early information on these outcomes at CD4 counts 
>500cells/µL. The results from these studies might be of benefit to DOH as the new policy of 
ART regardless CD4 is rolled out in South Africa.    
 
The study presented in chapter 4, ‘Attrition when providing antiretroviral treatment at CD4 
counts >500cells/µL at three government clinics included in the HPTN 071 (PopART) trial in 
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South Africa’, evaluated the impact of routine initiation of ART at baseline CD4 counts 
>500cells/µL at DOH clinics on attrition during early ART. 
 
The study presented in chapter 5, ‘Incidence of Tuberculosis amongst HIV-positive 
individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 
(PopART) trial in South Africa’, evaluated the impact of routine initiation of ART at baseline 
CD4 counts >500cells/µL at DOH clinics on TB incidence during early ART.   
 
The study presented in chapter 6, ‘Renal dysfunction in a cohort of adults starting 
antiretroviral treatment at baseline CD4 counts > 500cells/µL in the HPTN 071 (PopART) 
study in South Africa’, evaluated the impact of routine initiation of ART at baseline CD4 
counts >500cells/µL on the incidence of renal dysfunction during early ART. 
 
The study presented in chapter 7, ‘Baseline CD4 Count and Adherence to Antiretroviral 
Therapy: A Systematic Review and Meta-Analysis’, evaluated the association between 
baseline CD4 and ART adherence in studies published between January 2004 and September 
2015.  
 
Chapter 8, the discussion chapter, summarises the key findings of this research and 
discusses how these findings can contribute toward improving HIV treatment services in 
high-burden settings. The chapter also highlights operational gaps identified through 
completion of the studies that may be of importance to health care providers.  
 
Chapter 9 lists additional publications I contributed to since January 2014, referenced in this 
PhD dissertation.  
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Chapter 2: Outline of the HPTN 071/Population Effects of 
Antiretroviral Therapy to Reduce HIV Transmission (PopART) trial  
This chapter provides an overview of the HPTN 071 (PopART) trial in both Zambia and South 
Africa. Additional information on clinic activities in South Africa relevant to the completion 
of the studies presented in chapters 4 to 6 is also provided.  
 
The HPTN071 (PopART) trial is a three-armed community randomised study set in Zambia and 
South Africa, which aims to determine the impact of two community-level combination 
prevention packages on population-level HIV incidence. PopART is funded by the United 
States National Institutes for Health (NIH), the President’s Emergency Plan For AIDS Relief 
(PEPFAR) and the Bill & Melinda Gates Foundation. PopART is implemented in close 
partnership between study partners in the United Kingdom, United States, Zambia and South 
Africa; with extensive collaboration with Zambian and South African DOH and PEPFAR 
implementing partners. PopART implementation of field activities started in January 2014 and 
is scheduled to end in June 2018.  
 
2.1 HPTN 071 (PopART trial) overview  
For PopART, a community is defined as the catchment population of a DOH primary 
healthcare (PHC) clinic. (1, 2) The total population per PopART community averages 55,000 
individuals. Within each country, communities were matched based on the best available 
estimates of HIV prevalence and ART coverage. The 21 PopART communities were divided 
into seven matched triplets, with three triplets in South Africa and four in Zambia. Sites in 
South Africa were selected based on the criteria listed below. 
 
 Burden of HIV/TB  
 Drainage population of the clinic > 25 000 adults  
 A functioning ART service  
 Clinic must have capacity for expansion to meet scale up demands  
 Perceived low mobility of population 
 Compatibility with other sites to form triplet 
 Proximity to Cape Town  
 Existing knowledge of site from the Zamstar study   
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In each matched triplet, one community was randomly allocated to Arm A, B or C (Table 1). 
The PopART intervention targeted all individuals in the Arm A and B study communities and 
was delivered jointly in the community by a cadre of community HIV care providers (CHiPs) 
and at DOH PHC clinics. From October 2016, ART guidelines, in South Africa and Zambia 
recommended ART regardless of CD4 count, (3, 4) and from that time Arms A and B therefore 
offered the same intervention. Despite these changes, PopART remained well powered to 
evaluate the primary outcome. The primary outcome of HIV incidence is evaluated in a 
randomly selected research cohort, the Population Cohort (PC), which aims to recruit 44,500 
HIV-positive and negative participants aged 18 to 45, approximately 2000 from each of the 
21 communities (Table 1). (5) 
 
Table 1: Outline of PopART trial  
ARM A ARM B ARM C 
CHiPs* CHiPs   
Standard of care  
(No CHiPs)  
ART irrespective of CD4 
Count at DOH clinics  
ART as per country guidelines  
at DOH clinics **  
PC  PC  PC  
*CHiPs will visit all households in the PopART communities allocated to Arms A and B.  
** From October 2016 ART guidelines recommended ART regardless of CD4 count and from that time Arm A 
and B therefore offered the same intervention.  
 
Extensive community consultation was completed during the development and 
implementation of the PopART trial. Study-specific community advisory boards were 
established in both Zambia and South Africa. Ongoing study progress is discussed at regular 
monthly community advisory board (CAB) meetings. Additional ad hoc meetings are 
scheduled to discuss any specific challenges that arise during study implementation. (1, 2)  
 
2.1.2 PopART trial objectives  
Analysis of trial objectives is completed by comparison across Arms A, B and C of the trial.  
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Primary Objective:  
To measure the impact of the two intervention packages delivered to Arms A and B on HIV 
incidence by enrolling and following a random sample of adults (the Population Cohort) in the 
trial communities over four annual rounds. (2) 
Secondary objectives evaluated using PC data: 
1. To measure the impact of the two intervention packages on: 
 community viral load 
 HSV-2 incidence 
 uptake of HIV testing and retesting over the entire study period 
 ART screening and uptake 
 sexual risk behaviour 
 uptake of male circumcision 
 HIV-related stigma 
 ART adherence and viral suppression (if funding is identified) 
 ART drug resistance (funding is identified). 
Secondary objectives evaluated using ChiPs and DOH clinic data 
2. To measure the impact of the two intervention packages on: 
 Time between HIV diagnosis and initiation of care 
 Retention in HIV care  
 HIV disease progression and death 
 ART toxicity based on clinic records 
 Case notification rate of tuberculosis 
 Uptake of PMTCT 
 Uptake of male circumcision. 
 
(Additional secondary objectives, including costing evaluations, will be evaluated through a 
number of nested ancillary studies.) 
 
2.2 PopART interventions in Zambia and South Africa  
Arm A communities received the full intervention package, which included HIV prevention 
services delivered by community HIV care providers (CHiPs) through door-to-door visits 
throughout the whole community. As well as ART regardless of CD4 count for all HIV-positive 
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individuals at DOH clinics (Table 1). (1, 2) Arm B was provided the same community 
interventions as Arm A, but with provision of ART according to prevailing South African and 
Zambian DOH guidelines. In the control arm (Arm C) there are no CHiPs workers and HIV, TB 
and sexually transmitted infections (STIs) services are conducted as per DOH guidelines.  
 
2.2.1 CHiPs interventions in Zambia and South Africa  
The CHiPs teams routinely visit each household in the communities, at least annually for 
four years (2013 to 2017) with field work ending in December 2017. Included in the ChiPs 
visits were:  
 Household HIV counselling and testing (HTS) using HIV POCT in line with DOH guidelines 
 Counselling on sexual risk reduction 
 Condom provision 
 STIs and TB, including collection of sputum for TB diagnostics if symptomatic 
 Promotion of voluntary male medical circumcision (VMMC) among HIV-negative men 
(VMMC was also provided to any HIV-positive men who requested it.) 
 Active linkage to care for HIV, TB and VMMC. 
 
Activities of the CHiPs workers in the houses were guided by standardised questions 
presented on an electronic data capture (EDC) device. All individuals screened positive for 
HIV and/or TB were referred to the local clinic and followed up to confirm linkage to care 
through review of clinic data and repeat household visits. Data from the CHiPs EDC was 
uploaded to a central database in at the Desmond Tutu TB Centre daily using 3G internet 
connectivity and subsequently shared with the London School of Hygiene and Tropical 
Medicine (LSHTM) where it was integrated with data from Zambian sites for development of 
monitoring reports and evaluation of secondary outcomes.  
 
2.2.2 Clinic interventions in Zambia and South Africa 
HIV-positive individuals referred by ChiPs teams were fully assimilated into DOH care at the 
clinics and managed the same as individuals testing HIV-positive with other service 
providers. All services at clinics included in the PopART trial were delivered according to 
DOH standard care, with one exception; at clinics allocated to Arm A, all HIV-positive 
individuals were eligible for ART regardless of CD4 count from January 2014, ahead of 
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recent changes to WHO and in-country ART guidelines. (3, 4, 6) Both countries 
recommended a triple therapy first-line ART regimen with two NRTIs, tenofovir plus either 
lamivudine (3TC) or emtricitabine (FTC), along with an NNRTI (EFV or NVP) for first-line ART. 
(3, 4) With the exception of validation of linkage to care, there is currently no linkage of 
CHIPs and DOH clinic data. Toward the end of the trial, a folder review process of clinic 
folders on individuals included in the PC who have given consent will be conducted to 
extract data to address secondary outcomes. A more detailed description of activities at the 
South African clinics, relevant to the studies presented in chapters 4 to 6 of this dissertation, 
is provided below.  
 
2.2.3 Detailed description of clinic interventions in the Western Cape, South Africa 
A fixed-dose combination of tenofovir, emtricitabine and efavirenz (TEE) was the first-choice 
ART regimen for first-line treatment at all clinics participating in PopART in the Western 
Cape. According to Western Cape ART guidelines, (7) tenofovir was contraindicated in 
clients with baseline estimated glomerular filtration rate (EGFR) <50 mL/min, in which case 
tenofovir was substituted with an alternative NRTI (zidovudine or abacavir), as part of a 
triple therapy regimen. Second-line treatment, for individuals failing first-line, included 
protease inhibitors and ritonavir-boosted protease inhibitors combined with two NNRTIs. 
There was no standard third-line regimen. Individuals failing second-line treatment were 
referred for genotypic resistance testing and further ART that might also have included 
integrase inhibitors, such as DTG. ART pharmacy pick-up dates were initially scheduled 
monthly, and then up to once every three months, once clients were assessed as stable on 
ART.  
 
Routine laboratory monitoring in South Africa was completed by the National Health 
Laboratory Services (NHLS), and included routine measurement of CD4 cell count at four 
and 12 months of ART and of viral load at four months, 12 months and then annually. (4) 
DOH standard adherence and retention interventions were retained throughout PopART to 
ensure sustainability and strengthened through CHiPs activities. Stable ART clients meeting 
standardised criteria were routinely referred to clinic or community-based adherence clubs. 
(8) The work of clinic and community-based staff was integrated by their attendance at joint 
clinic operational meetings, (1, 4) and discussed at regular partnership meetings attended 
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by DOH, DTTC and PEPFAR implementing agency staff.  PopART support for clinics included 
in the trial will end in June 2018.  
 
All individuals starting ART and TB treatment in South Africa were registered on the DOH 
routine HIV monitoring system, Tier.net, (9) and the electronic TB register (ETR.net), (10) 
respectively. Aggregate Tier.net data, detailing the numbers of clients starting ART, are 
collected for PopART and included in the PopART intervention quarterly monitoring reports.  
 
2.3 The population cohort (PC) in Zambia and South Africa 
PC participants, aged 18 to 45, were randomly selected from randomly selected households in 
each of the 21 PopART trial communities in Zambia and South Africa. (1, 2) All households 
within the defined trial community boundaries were initially enumerated through a census in 
2013, prior to the study commencing. If the selected individual in a household declined to 
participate in the PC cohort, another adult in the household was randomly selected for trial 
inclusion. If there were no eligible adults willing to consent to the study, the household was 
replaced with another sample from the household list.  
 
PC participants were visited annually for three rounds, between 2013 and 2016, namely, PC0, 
PC12 and PC24. PC36 began in September 2017 and will end in June 2018. At each annual 
round visit, participants were requested to complete a questionnaire and give blood for 
measurement of trial endpoints, including HIV. Laboratory-based HIV testing was first 
completed in-country using Abbott Architect HIV Ag/Ab Combo assay. A subsequent 
confirmatory HIV test was completed by the Network Laboratory (NL) in the United States 
using the 4th-generation Architect HIV test. These laboratory HIV results were not made 
available to the participant. All PC participants who do not know their HIV status or were 
reported as HIV-negative were offered an HIV point of care test (POCT).  The HIV POCT kits 
used by PopART PC teams in South Africa varied. Between January and June 2014, First 
Response™ HIV 1-2-0 Card Test was used for screening and Alere Determine™ HIV-1/2 for 
confirmation, between July and December 2014, SD Bioline HIV-1/2 3.0 was used for 
screening and Alere Determine™ HIV-1/2 test for confirmation, and from January to June 
2015, ADVANCED QUALITY™ Rapid Anti-HIV (1&2) Test  and Abon HIV 1/2/O Tri-line test 
were used for screening and confirmation respectively. In Zambia, Alere Determine™ HIV-
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1/2 test and Uni-Gold HIV were used for screening and confirmatory tests respectively, 
consistently from January 2014. In August 2015, PopART sites in South Africa changed to 
Alere Determine™ HIV-1/2 test and Uni-Gold HIV test in line with the Zambian sites.  
 
Data on HIV POCT results were initially recorded on a paper form and subsequently entered 
into the PC database. All PC questionnaire data were captured on an EDC during the household 
visit and, together with laboratory test results, uploaded to a central database accessible from 
South Africa, Zambia, the United Kingdom and the United States.  
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Chapter 3: Understanding low sensitivity of community-based HIV 
rapid testing: experiences from the HPTN 071 (PopART) trial in 
Zambia and South Africa. 
 
Citation: Bock P, Phiri C, Piwowar-Manning E, Kosloff B, Mandla N, Young A, et al. 
Understanding low sensitivity of community-based HIV rapid testing: experiences from the 
HPTN 071 (PopART) trial in Zambia and South Africa. Journal of the International AIDS 
Society. 2017 Aug 29; 20(Suppl 6):19-27. 
 
Study design overview  
For this study a series of cross sectional analyses, completed quarterly between January 
2014 and June 2016, were used to evaluate HIV POCT sensitivity amongst PC participants 
who accepted both HIV POCT and HIV serum testing at the PC0 and/or PC12 annual visits. 
The study also described quality assurance (QA) of HIV POCT activities and quality control 
(QC) of HIV POCT kits and QA/QC results over the same time period. Data for this study were 
accessed primarily from the PC database and integrated with additional data from PC 
QA/QC activities. These data were further integrated with additional data on PC participants 
who had a discordant HIV POCT result collected either when they were re-visited by the PC 
teams to follow up on their incorrect HIV POCT result, or from their DOH clinics records. This 
study addressed the following PhD objective:  
To evaluate within the PopART PC the accuracy of household-based HIV POCT.  
Table 2: HTS study outline  
Primary 
outcome 
Study site  Study 
period  
Inclusion 
criteria  
Data sources  
HIV POCT 
sensitivity 
PC0 and PC12 
Zambia and 
South Africa  
1 January 
2014 to end 
June 2016 
PC participants 
who accepted 
both laboratory 
and POCT HIV 
tests during 
PC0 and or 
PC12 
PC database, 
PC process 
data and DOH 
clinic records 
 
 
Author contributions to study: I am co-principal investigator in the HPTN 071 PopART trial 
in South Africa and have been intimately involved in implementation of the PopART PC. For 
this study I worked closely with the senior authors to develop the study design. I also 
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worked closely with the HPTN statistical centre (AY and DD) to develop the statistical 
analyses. I was the corresponding author in submission and publication of the study and 
jointly with the senior author coordinated development, submission, edits to reviewer 
comments and finalisation of the manuscript. All authors contributed towards development 
of the manuscript and reviewed drafts. All the authors read and approved the published 
version. 
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Chapter 4: Attrition when providing antiretroviral treatment at CD4 
counts >500 cells/µL at three government clinics included in the 
HPTN 071 (PopART) trial in South Africa 
 
Unpublished: Under review with Plos One.  
 
Study design overview  
For this study, a cohort study design was used to evaluate the impact of baseline CD4 count 
>500 cells/µL on attrition from ART care during early ART amongst adults (≥18 years) 
starting ART at the three PopART Arm A clinics in South Africa. A detailed description of 
relevant clinic activities was provided in chapter 2. All adults starting ART at the three study 
clinics between January 2014 and End November 2015 were screened for inclusion in the 
study sample (Table 3). Having a reported baseline CD4 count was an inclusion criterion for 
the study. A total of 2423 adults, with a reported baseline CD4 count, were included in the 
study sample. Attrition included individuals no longer retained in ART care due to loss to 
follow-up or death. Individuals were defined as experiencing attrition if they were more 
than three months late for a pharmacy pick-up appointment. All individuals were followed 
up until the date of attrition, elective transfer to another facility (TFO) or end May 2016; 
whichever occurred first. Data were extracted from the following sources; i) the routine HIV 
monitoring system (Tier.net) ii) the electronic TB register (ETR.net) and iii) from NHLS 
routine reports. This study addressed the following PhD objective:  
 
To evaluate the impact of routine initiation of ART at baseline CD4 counts >500 cells/µL at 
DOH clinics on attrition during early ART 
Table 3: Attrition study outline  
Primary 
outcome 
Study site  Recruitment 
period 
Exclusion 
criteria  
Follow-up  Data sources  
Attrition  Three SA 
PopART Arm 
A clinics 
1 January 
2014 to end 
November 
2015 
Missing 
baseline CD4 
count  
Until attrition 
TFO or end 
May 2016 
Tier.net, 
ETR.net and 
NHLS reports 
 
Author contribution: I was responsible for setting up this study cohort in partnership with 
DOH and PEPFAR implementing partners. Along with co-authors (GF, NF, SF and NB), I 
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conceptualised this study and completed the statistical analysis with support from SF and GF. 
All authors contributed toward development of the manuscript and reviewed drafts including 
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Abstract  
Introduction  
WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals.  This study 
evaluated the association between baseline CD4 count and attrition in a cohort of HIV 
positive adults initiating ART at three department of health (DOH) clinics routinely providing 
ART at baseline CD4 counts >500cells/µL for the HPTN 071 (PopART) trial.  
 
Methods  
All clients attending the DOH clinics were managed according to standard care guidelines 
with the exception that those starting ART outside of pertinent local guidelines signed 
research informed consent. DOH data on all HIV-positive adult clients recorded as having 
initiated ART between January 2014 and November 2015 at the three study clinics was 
analysed. Attrition, included clients lost to follow up or died, and was defined as ‘being 
three or more months late for an antiretroviral pharmacy pick-up appointment’. All clients 
were followed until attrition, transfer out or end May 2016.  
 
Results  
A total of 2423 clients with a median baseline CD4 count of 328 cells/µL (IQR 195-468) were 
included of whom 631 (26.0%) experienced attrition and 140 (5.8%) were TFO. Attrition was 
highest during the first six months of ART (IR 38.3/100 PY; 95% CI 34.8-42.1). Higher attrition 
was found amongst those with baseline CD4 counts > 500 cells/µL compared to those with 
baseline CD4 counts of 0-500 cells/µL (aHR 1.26, 95%CI 1.05 to 1.52) This finding was 
confirmed on subset analyses when restricted to individuals non-pregnant at baseline and 
when restricted to individuals with follow up of > 12months.  
Conclusions  
Attrition in this study was high, particularly during the first six months of treatment. 
Attrition was highest amongst clients starting ART at baseline CD4 counts > 500 cells/µL. 
Strategies to improve retention amongst ART clients, particularly those starting ART at 
baseline CD4 counts >500cells/µL, need strengthening. Improved monitoring of clients 
moving in and out of ART care and between clinics will assist in better understanding 
attrition and ART coverage in high burden countries.   
Introduction  
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There are 36.7 million HIV positive individuals and 19.5 million people on antiretroviral 
treatment (ART) worldwide (1). UNAIDS has set global HIV treatment targets of 90:90:90; 
90% of HIV positive individuals knowing their HIV status, of which 90% are on ART, of which 
90% are virally suppressed (2). To achieve the sustained viral suppression required to 
prevent progression to AIDS disease in HIV positive individuals and to limit onward viral 
transmission of HIV, high levels of retention in ART care and adherence to medication are 
required (3, 4).  
 
Retention in ART programmes in high burden settings is extremely challenging. A recent 
systematic review, which included 1.5 million participants from African and Asian 
programmatic studies (75% from Africa), the majority of whom started ART at baseline CD4 
counts < 200cells/µL, found 17% and 26% of individuals on ART lost to follow up or died 
(attrition) at 12 months and at 24 months respectively (5). The association between baseline 
CD4 count and attrition varies, with some programmatic studies having reported decreased 
(6) and some showing increased attrition at higher CD4 counts (7-9). The median baseline 
CD4 counts in these published studies, however, was low with a high proportion of 
individuals starting ART at CD4 counts <200cells/µL and mortality may have contributed 
extensively to attrition amongst individuals with lower CD4 counts.  
 
Following results of the START and TEMPRANO randomised control trials (RCTs) in 2015 (10, 
11), WHO guidelines have recommended ART for all PLHIV regardless of CD4 count (12). 
There are, however, very limited published data evaluating the impact of routine provision 
of ART at CD4 counts > 500cells/µL on attrition from ART programmes in high burden 
settings. Concerns also remain that increased numbers of clients starting ART at baseline 
CD4 counts > 500cell/µL, when clinically well, may be associated with increased attrition 
(13).  This study evaluated the association between baseline CD4 count > 500cells/µL and 
attrition in a cohort of adults initiating ART regardless at three department of health (DOH) 
clinics in the Western Cape Province, South Africa.  
 
Methods 
Study setting  
This study was conducted at three DOH primary health care (PHC) clinics included in the 
‘Population effect of antiretroviral therapy to reduce HIV incidence’ HPTN 071 (PopART) trial 
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in the Western Cape (WC), South Africa.  A full description of the HPTN 071 (PopART) trial 
design has been published (14). The communities surrounding the three study clinics 
received the full HPTN 071 (PopART) intervention which consisted of household delivery of 
an HIV combination prevention package, including HIV rapid testing in the house by 
community HIV care providers (CHiPs), referral to the clinics and active linkage to ART care. 
CHiPs routinely visited clients annually with more intensive follow up when clinically 
indicated e.g. after HIV diagnosis (14). 
 
Two clinics were located in the metro district (Metro 1 and 2) and one in a rural district 
(Rural 1). These study clinics offered ART regardless of CD4 count for all HIV positive clients 
aged 18 or older. During the study period for standard care at other clinics DOH ART 
guidelines recommended ART initiation at baseline CD4 count ≤ 350 cells/µL until January 2015 and 
thereafter at baseline CD4 count ≤500cells/µL (15). All clients attending the study clinics 
received standard care as per DOH ART guidelines with the exception that ART was provided 
to all HIV positive individuals and individuals starting ART outside of pertinent DOH 
guidelines signed informed consent. 
 
A fixed-dose combination of tenofovir, emtricitabine and efavirenz (TEE) was used for first 
line treatment.  Pharmacy pick up dates for collection of TEE were initially scheduled 
monthly, then every two to three months once clients were assessed as stable on ART by a 
clinician. CD4 count was routinely measured at four months and 12 months of ART and viral 
load at 4 months, 12 months and then annually (15). All routine laboratory services were 
provided by the National Health Laboratory Service (NHLS). All ART clients start ART were 
registered on the ART routine monitoring system, Tier.net (16). For sustainability, standard 
adherence and retention interventions provided by DOH facilities were continued 
throughout HPTN 071 (PopART), complimented by the work of the CHiPs teams. As per ART 
guidelines and HPTN 071 (PopART) standard operating procedures, all ART clients should 
have been supported by clinic-based adherence counsellors, community-based adherence 
workers (CCWs) and CHiPs teams. The work of the clinic adherence counsellors, CCWs and 
CHiPs was integrated through joint attendance of clinic operational meetings (14, 15). Stable 
ART clients were routinely referred to adherence clubs, either at the facility or in the 
community, according to DOH adherence club guidelines (17).  
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Cohort overview and definitions  
This study included data on all clients 18 years and older recorded in Tier.net as initiating 
ART at the three study clinics, between 1 January 2014 and 30 November 2015 (14, 16). 
Follow up continued until 30 May 2016 the time of administrative data censor.  Clients with 
previous ART exposure but no longer on ART, restarting ART at the study clinics were eligible 
for inclusion in the study sample. Clients transferred into the study clinics from another ART 
clinic, already on ART, during this period were excluded from the study sample. Baseline 
CD4 was defined as the most recent CD4 count within the six months prior to starting ART. 
Baseline TB treatment was defined as having started TB treatment within the 6 months prior 
to starting ART. Clients were routinely dispensed between 1 and 3 months ART medication 
at their last recorded clinic visit. The date of their next scheduled visit was calculated based 
on the number of days medication dispensed. The primary outcome, attrition, was defined 
as ‘being three months or more late for this calculated next scheduled visit. All clients were 
followed up for a minimum of six months. Death was not analysed separately due to 
significant under-recording in Tier.net. Clients electively transferred to another facility were, 
in line with Tier.net definitions, defined as transfer outs (TFOs).  
 
Data management  
All data were initially extracted from Tier.net except the data on baseline TB treatment 
which were extracted from the electronic TB register (ETR.net). If the baseline CD4 count 
results were missing from Tier.net, these were extracted from the National Health 
Laboratory Services (NHLS) databases. Data from Tier.net were linked to ETR.net data 
through a matching algorithm utilising name, surname and date of birth in Microsoft SQL 
ServerTM. CD4 count data, extracted from the NHLS database, were linked to data in Tier.net 
using the WC DOH ‘Clinicom number’ as unique clinic identifier in Stata13TM. Pharmacy pick 
up data recorded in Tier.net was used to calculate the date for next scheduled clinic 
appointment. Data cleaning and validation included cross-referencing data fields within 
Tier.net and across Tier.net, NHLS and ETR.net databases. Data elements in Tier.net that 
were adjudged to have with high rates of missing or incorrect data, e.g. baseline WHO stage 
and data on adherence club attendance were excluded from analysis.   
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Analysis    
Baseline characteristics were described for continuous and categorical variables and 
distribution across CD4 strata was assessed using Chi Squared tests and Kruskal-Wallis tests. 
Incidence rates were estimated and time-to-event analyses were conducted using Kaplan 
Meier survival and smoothed hazard estimates. Clients were censored on either the date of 
attrition, TFO, or on 30th May 2016 (end of the study); whichever was the earliest. 
Unadjusted and adjusted comparisons of the hazard of attrition at different baseline CD4 
count strata were carried out using Cox regression. Potential confounding baseline 
characteristics for inclusion in the adjusted analysis were selected a priori based on clinical 
relevance; these included: age, sex, pregnancy status, TB treatment, clinic, previous ART 
exposure of more than 3 months and year of ART start. Baseline CD4 count strata were 
chosen to align with previous ART guideline cut offs. (18) Proportional hazards assumptions 
were checked with scaled Schoenfeld residuals. Likelihood ratio tests were used to estimate 
P values in regression models where categorical variables had more than two strata. For 
each variable included in the model, the category chosen as baseline for comparison (HR=1) 
was based on sample size and clinical significance. Multivariate logistic regression, including 
the same baseline characteristics, with the exception of baseline CD4 count was used to 
compare baseline characteristics of clients excluded from analysis due to missing baseline 
CD4 count and those included in the  study sample. All analyses were performed using Stata 
version 13 (StataCorp LP, College Station, TX, USA).  
 
Ethics statement  
The HPTN 071 (PopART) trial was approved by the Stellenbosch University Health Research 
Ethics Committee (SU HREC) (Ref. No. N12/11/074) and the London School of Hygiene and 
Tropical Medicine Research Ethics Committee (Reference number 6362). All clients initiating 
ART outside local DOH guidelines for HPTN 071 (PopART) gave written informed consent. 
Further permission for this study and the use of individual level  data from the WC DOH 
sources (Tier.net, ETR.net and NHLS) with a waiver for informed consent has also been 
received from SU HREC (reference number N12/11/074A), the Western Cape Government 
(Reference no. WC_2015RP51_715) and City of Cape Town (Reference no. 10529).  
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Results  
A total of 2593 clients who started ART at the study clinics between 1 January 2014 and end 
November 2015 were screened for inclusion in the study, of whom 170 (6.6%) were 
excluded due to missing baseline CD4 counts. This left a sample of 2423 clients included in 
the analysis. The distribution of clients by baseline CD4 count strata was 631 (26.0%) at CD4 
0-200 cells/µL, 708 (29.2%) at CD4 201-350 cells/µL, 582 (24.0%) at CD4 351-500 cells/µL 
and 502 (20.7%) at CD4 >500 cells/µL (Table 1). Median baseline CD4 count was 328 cells/µL 
(IQR 195-468 cells/µL). Most clients were women, 1643 (67.8%), and median age was 31 
(IQR 26-38) years.  One hundred and forty two (8.6% of women) clients were confirmed 
pregnant at ART initiation. A total of 285 (11.8%) clients were on TB treatment at baseline, 
this proportion ranged from 25.7% among those with CD4 counts ≤200 cells/µL down to 
5.2% among those with counts >500 cells/µL. More clients were treated at metro clinics; 
1022 (42.2%) and 947 (39.1%) at Metro 1 and 2 respectively with 454 (18.7%) treated at the 
rural clinic. A small number of clients, 49 (2.0%) had previous ART exposure of more than 
three months.  The majority of clients started ART in 2015; 1733 (71.5%) compared to 690 
(28.5%) in 2014.  
 
Overall, 631 (26.0%) clients experienced attrition during 2389 person years (PY) of follow up 
(Incidence Rate (IR): 26.4/100 PY) and 140 (5.8%) were TFO. Amongst individuals 
experiencing attrition, 11 (1.7%) were documented in Tier.net as having died. Median 
baseline CD4 count amongst those individuals who died was 34 cells/µL (IQR: 63-155). 
Median follow up time was 11.2 (IQR 7.2-16.1) months. Cumulative numbers of clients 
experiencing attrition was 418 (17.3%), 561 (23.2%), 613 (25.3%), 631 (26.0%) at 6, 12, 18 
and 24 months on ART respectively). Kaplan Meier estimates showed higher attrition 
amongst clients with baseline CD4 counts > 500cells/µL compared to ≤ 500cells/µL (P<0.02) 
(Figure 1) Attrition  peaked at three months across all CD4 count strata and was higher 
during the first 6 months of ART compared to longer treatment durations; IR: 38.6/100 PY 
(95% CI 35.1-42.4) from 0 to 6 months ART, 19.2/100 PY (95% CI 16.3-22.6) from 7 to 12 
months ART, 14.3 /100 PY (95% CI 10.9-18.7) from 13 to 18 months ART and 11.8 /100 PY 
(95% CI 7.4-18.7) from 19 to 24 months ART (Table 2).  
 
Adjusted Cox regression analysis using the full model showed higher attrition amongst 
clients with baseline CD4 counts > 500 cells/µL (aHR 1.26, 95%CI 1.05 to 1.52; (P=0.014) 
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compared to 0-500cells/µL (Table 3)There was higher attrition amongst clients aged 18-25 
years when compared to those aged 26-35 years (aHR 1.30, 95% CI 1.07-1.58). The hazard of 
attrition was lower amongst clients starting ART in 2014 compared to 2015 (aHR 0.81, 95% 
CI 0.66--1.00; P=0.051). There were no significant differences in attrition between men and 
women or between study clinics in adjusted analysis.  
 
Additional multivariate analysis that further stratified baseline CD4 count showed higher 
attrition in individuals with baseline CD4>500cells/µL when compared to those with 
baseline CD4 counts 350-500 cells/µL (aHR 1.42, 95%CI 1.12-1.79) (Supplementary data file 
1). There was no significant difference in attrition when comparing clients with baseline CD4 
counts 350-500 cells/µL to those with baseline CD4 counts 201-350 cells/µL or 0-200 
cells/µL.  The higher attrition in individuals with baseline CD4 counts >500 cells/µL persisted 
in subset analyses restricted to 2281 individuals who were non-pregnant at the time of ART 
initiation (aHR 1.29, 95%CI 1.07-1.57) (Supplementary data file 2) and in subset analysis 
restricted to 1100 individuals with follow up of more than 12 months (aHR 1.29, 95%CI 1.07-
1.57) (Supplementary data file 3).  
 
Multivariate logistic regression of factors associated with missing baseline CD4 counts 
showed increased rates of missing baseline CD4 counts amongst clients who were pregnant 
at baseline (aOR 2.40, 95% CI 1.35-4.26) and amongst those starting ART in 2014 (aOR 20.2, 
95% CI 8.83-46.54) compared to 2015. Being treated at Metro 2 (aOR 0.29, 95% CI 0.12-
0.69) and the rural clinic (aOR 0.01, 95% CI 0.00-0.04) were associated with decreased rates 
of missing baseline CD4 counts.  
 
Discussion  
In this study we found, in a cohort of clients receiving ART regardless of CD4 count at three 
DOH clinics, we found high rates of attrition, higher  amongst clients who started ART with 
baseline CD4 counts > 500cells/µL compared to those with baseline CD4 count 0-500 
cells/μL. This finding was confirmed in subset analyses restricted to individuals non- 
pregnant at baseline and when restricted to individuals with follow up time of > 12 months. 
When dividing baseline CD4 count to four strata, attrition was higher amongst clients with 
baseline CD4 counts > 500 cells/µL compared to those with baseline CD4 counts of 350-500 
cells/μL.  
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The cumulative proportion of clients experiencing attrition in this paper was comparable to 
that reported by DOH for the corresponding health  districts during the same time period 
(19); as well as with data from a large systematic review of programmatic data from Africa 
and Asia (26% at 24 months ART) (20).   
 
This finding of higher attrition amongst individuals with higher baseline CD4 counts, who 
may be more likely to be clinically well when starting ART, supports findings from previous 
studies. (7-9). The underlying reasons for the higher attrition in this group in this study is not 
clear   and may have been driven by psychosocial and health systems factors not measured 
in the study.   The extent to which mortality contributed to attrition was not accurately 
documented in Tier.net. Although mortality as a cause of attrition is decreasing in Africa 
(21), it remains a significant contributor; particularly during the initial six months on ART 
(22, 23). Published studies, with lower median baseline CD4 counts, where clients 
experiencing attrition  were  actively followed up with extraction of data from additional 
sources such as death registries, showed that approximately 40% of clients documented as 
lost to follow up form ART programmes have in fact died (21). The START and Temprano 
RCTs showed significantly lower mortality amongst ART clients with baseline CD4 counts 
>500 cells/µL (10, 11), and it is therefore plausible that higher attrition  amongst those with 
baseline CD4 counts > 500 cells/µL in this study was driven more by individual choice than 
by mortality. 
 
The peak in attrition during the first six months on ART across all CD4 strata emphasises the 
need for additional retention strategies at clinics during early ART. The higher attrition 
amongst younger clients (18 to 25 years) is in keeping with previously published data and 
highlights the need to continue to strengthen interventions and support focused on this age 
group (24, 25). Attrition was also higher amongst clients starting ART in 2015 compared to 
2014. This may be associated with overburdening of study clinic resources as a result of 
increased numbers of clients on ART over time (26, 27). The WC DOH has a well-established 
adherence club programme (17) and further development this model of care may be 
effective in decongesting clinics and improving outcomes (28, 29).  
 
Despite a well-established ART service in the Western Cape since 2004 and provision of ART 
regardless of CD4 count for HPTN 071 (PopART) since January 2014 a high proportion of 
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clients (26.0%) in this study initiated ART at baseline CD4 counts < 200 cells/µL. This 
persistence of low baseline CD4, even in the context of ART regardless of CD4 count, is a 
serious concern. Interventions aimed at promoting earlier ART uptake should therefore 
continue to be a priority and further strengthened. A recent systematic review of 
community and clinic based interventions aimed at increasing uptake of ART in sub-Saharan 
Africa found home based HIV testing and improved efficiencies and structure at clinics to be 
effective in improving ART uptake (20). The evidence was, however, reported to be of low 
quality and the authors identified an urgent need for well-structured studies on the topic. 
The review also raised concerns about a lack of focus on retention on ART in the literature 
(20). 
 
Strengths and weaknesses  
The study has a number of key strengths. Data used in the analysis was part of a high quality 
routine dataset, strengthened by prospective data quality improvement for HPTN 071 
(PopART) and clients were provided ART regardless of CD4 count ahead of recent changes to 
WHO and local guidelines.  There were high rates of completeness in key data fields with 
only a small proportion (6.6%) of eligible clients excluded from the analysis due to missing 
baseline CD4 count results. There was also high similarity in baseline characteristics 
associated with attrition between clients excluded due to missing baseline CD4 counts and 
those included in the study. The three study clinics were typical of metro and rural clinics in 
the Western Cape and clinic activities were closely aligned to standard care during the study 
period, supporting generalisability of study findings. Another major strength was the use of 
an objective measure for determination of attrition (pharmacy pick up date).  
 
There are, however, a number of limitations to consider. Factors not measured by the 
available date set including psychosocial and health systems factors may have confounded 
the association between baseline CD4 count and attrition. In this regard; although activities 
at clinics included in this study were closely aligned for PopART and choice of clinic was not 
associated with attrition on multivariate analysis it is possible that clinic-related factors not 
measured in this paper may have confounded the primary analysis. Data and resources 
required for active follow up of individuals experiencing attrition to determine whether they 
had died or transferred to another facility without informing their current facility (silent 
transfers) were not available for this study. Published data show high rates of silent transfer 
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to other ART clinics amongst individuals documented lost to follow up at PHC clinics in the 
Western Cape.  (30)  The extent to which silent transfers, contributed to attrition in this 
study, as in many studies in in high burden regions, is unknown. These silent transfers are 
likely to have led to overestimation of attrition. Silent transfer may also have been higher 
amongst clients starting ART at baseline CD4 counts > 500cells/µL, as ART regardless of CD4 
counts was not available at neighboring clinics during the study period and clients may have 
come to the study clinic to initiate treatment and then returned to their ‘usual’ clinic.  
 
Throughout HPTN 071 (PopART) additional support was provided through staff and health 
systems support at clinics and in the community by CHiPs workers. This support was likely to 
have reduced overall attrition.   Although all ART clients were meant to have received 
community-based support from both DOH CCWs and/or CHiPs teams, it was not known 
what proportion of clients received community-based support or whether the community 
based support differentially impacted clients with baseline CD4 counts > 500cells/µL.  
 
There are further limitations affecting the generalisability of these results. Clients starting 
ART outside of pertinent DOH guidelines received additional counselling during the signing 
of research informed consent and which may have in turn reduced their risk of attrition 
amongst individuals with baseline CD4 >500cells/µL. In addition, CD4 count is often used in 
community narratives around ART and it is likely that community perception of the benefits 
of starting ART at baseline CD4 counts > 500 cells/µL will further develop over time as ART 
regardless CD4 count becomes standard care. This change in community perception may in 
turn be associated with decreased attrition amongst clients initiating ART at higher CD4 
counts (31). 
 
Conclusions  
We documented higher attrition amongst clients initiating ART at baseline CD4 counts > 
500cells/µL, highlighting an urgent need for retention with a focus on clients initiating ART 
at higher baseline CD4 counts. At the same time, strategies to improve earlier uptake of ART 
before their CD4 counts fall below 200cell/µL need to be strengthened. Monitoring systems 
that more accurately measure the contribution of death and silent transfers to attrition 
from ART programmes will assist in a better understanding of retention in ART programmes 
and ART coverage in high burden areas.   
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Tables  
Table 1: Baseline characteristics  
Units 0 - 200 cells/µl* 201-350 cells/µl 351-500 cells/µl >500 cells/µl Total P value**
All N (%) 631 (26.0) 708 (29.2) 582 (24.0) 502 (20.7) 2423
Female N (%) 355 (56.3) 463(65.4) 421 (72.3) 404 (80.5) 1643 (67.8)
Male N (%) 276 (43.7) 245 (34.6) 161 (27.7) 98 (19.5) 780 (32.1)
26-35 years N 312 (49.6) 311 (43.9) 272 (46.7) 227 (45.2) 1122 (46.3)
36-45 years N 167 (26.5) 138 (19.5) 109 (18.7) 87 (17.3) 501 (20.7)
46-55 years N 57 (9.0) 63(8.9) 46(7.9) 44(8.8) 210(8.7)
>55 years N 17 (2.7) 17(2.4) 13(2.2) 10(2.0) 57(2.3)
Pregnant at 
ART start 
Yes N 14 (3.9) 39(8.4) 41 (9.7) 48 (11.9) 142 (8.6%) P<0.0001
Baseline TB 
treatment
Yes N 162 (25.7) 56 (7.9) 41 (6.7) 26 (5.2) 285 (11.8) P<0.0001
Rural 1 N 88 (13.9) 113(15.9) 126(21.7) 127(25.3) 454 (18.7)
Metro 1 N 299 (47.4) 301 (42.5) 231 (39.7) 191 (38.1) 1022 (42.2)
Metro 2 N 244 (38.7) 294 (41.5) 225 (38.7) 184 (36.7) 947 (39.1)
Previous ART  
of > 3mths 
Yes N 27 (4.3) 10 (1.4) 7 (1.2) 5 (1.0) 49 (2.0) P<0.0001
2014 N 161 (25.5) 208 (29.4) 160 (27.5) 161 (32.1) 690 (28.5)
2015 N 470 (74.2) 500 (70.6) 422 (72.5) 341 (67.9) 1733 (71.5)
Clinic 
ART start year P=0.091
P<0.0001
P<0.0001
P<0.0001
33(29.0-40.0)  31(25.0-37.0) 31(26.0-37.0)  30(25.0-37.0)
134 (26.7) 534 (22.0)
Baseline factor
Gender
Age 
 31(26.0-38.0)Median (IQR) P=0.0001
18-25 years N% 79 (12.5) 179 (25.3) 142 (24.4)
Baseline CD4 count categories were chosen to align with ART previous ART guideline cut-offs.**The denominator 
for all %’s is the total sample for that CD4 count category with the exception of pregnancy where the denominator 
is limited to females in that CD4 count category. **Chi squared tests were used to evaluate differences across 
baseline CD4 strata for all categorical variables and the Kruskal–Wallis test for numerical variables (age).  
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Table 2: Summary of incidence rates of attrition by baseline CD4 count strata and time on ART  
 Time 
on ART  
         0 to 6 months          7 to 12 months         13 to 18 months                19 to 24 months  
Baselin
e CD4 
strata  
PY*  
No. 
LTF
U 
LTFU/100 
PY* 
PY 
No. 
LTF
U 
LTFU/100 
PY* 
PY 
No. 
LTF
U 
LTFU/100 
PY* 
PY 
No. 
LTF
U 
LTFU/100 
PY* 
0 - 200 
cells/µl 
283 108 
38.2                                     
(95%CI:31.1-
46.1) 
19
4 
33 
17,1 
86 13 
15,1 
36 5 
13,8 
(95%CI:12.1
-23.9) 
(95%CI:8.8-
26.0) 
(95%CI:5.7
-33.1) 
201 - 
350 
cells/µl 
323 119 
36,9 
22
3 
52 
23,3 
10
9 
11 
10,1 
50 8 
16,0 
(95%CI:30.1-
44.0) 
(95%CI:17.8
-30.6) 
(95%CI:5.6-
18.3) 
(95%CI:8.0
-32.2) 
351 - 
500 
cells/µl 
263 96 
36,50 
18
4 
22 
11,9 
87 9 
10,3 
38 2 
5,30 
(95%CI: 29.9
-44.6) 
(95%CI:7.9-
18.2) 
(95%CI:5.4-
19.8) 
(95%CI:1.3
-21.0) 
>500 
cells/µl 
223 95 
42,7 
15
6 
36 
23,1 
80 19 
23,8 
28 3 
10,6 
(95%CI:34.9-
52.2) 
(95%CI:16.7
-32.0) 
(95%CI:15.2
-37.3) 
(95%CI:3.4
-33.0) 
Total 
109
2 
418 
38,30 
75
6 
143 
18,9 
36
2 
52 
14,4 
15
2 
18 
11,8 
(95%CI:34.8-
42.1) 
(95%CI:16.1
-22.3) 
(95%CI:10.9
-18.9) 
(95%CI:7.5
-18.8) 
     *PY: Person Years **Incidence rates were calculated using the stptime command in Stata 13TM 
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Table 3: Cox regression modelling of baseline characteristics and attrition comparing baseline CD4 
categories > 500 cells/µL and 0-500 cells/µL.   
    
Crude  hazard ratio 
(95% CI)  P 
Adjusted hazard 
ratio (95% CI)  P 
Baseline CD4  
(cells/µL)  
> 500 1,24(1,03-1,48) 0,022 
  
1,26(1,05-1,52) 0,014 
  0-500 1 1 
Gender  
  
Male  1,06(0,9-1,25) 0,483 
  
1,23(1,03-1,47) 0,025 
  Female  1 1 
Age 
category  
  
  
  
  
18-25 1,29(1,07-1,56) 
<0.001 
  
  
  
  
1,3(1,07-1,58) 
0,002 
  
  
  
  
26-35 1 1 
36-45 0,91(0,73-1,12) 0,9(0,72-1,11) 
46-55 0,7(0,5-0,97) 0,69(0,49-0,96) 
>55 0,82(0,46-1,46) 0,8(0,45-1,44) 
Pregnant  at 
baseline Yes  1,36(1,01-1,82) 0,045 1,27(0,93-1,72) 0,134 
Clinic  
  
  
 
Metro 1  1 
0,279 
  
  
1 
0,137 
  
  
Metro 2  1,05(0,88-1,26) 1,16(0,95-1,43) 
Rural 1  0,89(0,71-1,11) 0,96(0,75-1,23) 
Baseline TB Yes  0,91(0,51-1,61) 0,744 0,94(0,53-1,68) 0,841 
Previous ART 
of > 3 months Yes  0,88(0,5-1,56) 0,667 0,91(0,51-1,61) 0,739 
Year ART start  
  
2014 0,86(0,72-1,02) 0,088 
  
0,81(0,66-1) 0,051 
  2015 1 1 
Proportional hazards assumptions were checked with scaled Schoenfeld residuals. Likelihood ratios were 
used to estimate P values in regression models where categorical variables had more than two strata. Model 
fits were assessed as good based on the likelihood ratio test statistic. Selection of baseline variable category 
for comparison (HR=1) was based on sample size and clinical significance. 
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Supplementary data  
Supplementary data file 1: Cox regression modelling of baseline characteristics and        attrition 
comparing all baseline CD4 categories.   
    
Crude  hazard ratio (95% 
CI)  P 
Adjusted hazard ratio (95% 
CI)  P 
Baseline CD4  
  
(cells/µL)  
> 500 1.39(1.1-1.76) 
0.049 
  
  
  
1.42(1.13-1.8) 
0.033 
  
  
  
351-500 1 1 
 201-
350 1.2(0.96-1.5) 1.19(0.95-1.48) 
0-200 1.16(0.92-1.47) 1.2(0.94-1.52) 
Gender  
  
Male  1.06(0.9-1.25) 0.483 
  
1.22(1.02-1.45) 0.031 
  Female  1 1 
Age 
category  
  
  
  
  
18-25 1.29(1.07-1.56) 
<0.001 
  
 
 
 
1.31(1.08-1.59) 
<0.001 
  
  
  
  
26-35 1 1 
36-45 0.91(0.73-1.12) 0.89(0.72-1.11) 
46-55 0.7(0.5-0.97) 0.69(0.49-0.96) 
>55 0.82(0.46-1.46) 0.81(0.45-1.44) 
Pregnant  at baseline Yes  1.36(1.01-1.82) 0.045 1.27(0.93-1.73) 0.125 
Clinic  
  
  
Metro 1  1 
  
 
 
1 
0.149 
  
  
Metro 2  1.05(0.88-1.26) 1.17(0.95-1.43) 
Rural 1  0.89(0.71-1.11) 0.97(0.76-1.25) 
Baseline TB  Yes  0.91(0.51-1.61) 0.744 0.92(0.51-1.64) 0.77 
Previous ART of > 3 
months Yes  0.88(0.5-1.56) 0.667 0.89(0.5-1.58) 0.687 
Year ART start  
  
2014 0.86(0.72-1.02) 
0.088 
  
0.81(0.66-1) 
0.046 
  2015 1 1 
Likelihood ratios were used to estimate P values in regression models where categorical variables had more 
than two strata. Model fits were assessed as good based on the likelihood ratio test statistic. Selection of 
baseline variable category for comparison (HR=1) was based on sample size and clinical significance. 
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Supplementary data file 2: Cox regression modelling of baseline characteristics and attrition 
comparing baseline CD4 categories > 500 cells/µL and 0-500 cells/µL restricted to individuals non-
pregnant at baseline.   
    
Crude  hazard ratio  
(95% CI)  P 
Adjusted hazard ratio  
(95% CI)  P 
Baseline CD4  
(cells/µL)  
> 500 1.24(1.02-1.5) 0.029 
  
1.29(1.07-1.57) 0.009 
  0-500 1 1 
Gender  
  
Male  1.1(0.93-1.3) 
0.287 
  
1.24(1.04-1.48) 
0.017 
  Female  1 1 
Age 
category  
  
  
  
  
18-25 1.3(1.06-1.59) 
0.003 
  
  
  
  
1.33(1.09-1.64) 
0.001 
  
  
  
  
26-35 1 1 
36-45 0.92(0.74-1.15) 0.91(0.73-1.13) 
46-55 0.69(0.5-0.97) 0.68(0.49-0.95) 
>55 0.83(0.47-1.49) 0.81(0.45-1.44) 
Clinic  
  
  
Metro 1  1 
0.225 
  
  
1 
0.076 
  
  
Metro 2  1.05(0.88-1.26) 1.23(0.98-1.55) 
Rural 1  0.86(0.68-1.1) 1.01(0.77-1.31) 
Baseline TB  Yes  0.95(0.54-1.68) 0.86 0.97(0.54-1.72) 0.913 
Previous ART of > 3 months Yes  0.97(0.55-1.72) 0.921 1(0.56-1.77) 0.997 
Year ART start  2014 0.81(0.67-0.97) 
0.024 
  
0.75(0.6-0.94) 
0.011 
    2015 1 1 
Analysis restricted to 2281 individuals non-pregnant at baseline. Likelihood ratios were used to estimate P 
values in regression models where categorical variables had more than two strata. Model fits were assessed as 
good based on the likelihood ratio test statistic. Selection of baseline variable category for comparison (HR=1) 
was based on sample size and clinical significance. 
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Supplementary data file 3: Cox regression modelling of baseline characteristics and attrition 
comparing baseline CD4 categories > 500 cells/µL and 0-500 cells/µL restricted to 
individuals with follow up of >12months.   
    
Crude  hazard ratio  
(95% CI)  P 
Adjusted hazard ratio  
(95% CI)  P 
Baseline CD4  
(cells/µL)  
> 500 1.24(1.02-1.5) 0.029 
  
1.29(1.07-1.57) 0.009 
  0-500 1 1 
Gender  
  
Male  1.1(0.93-1.3) 
0.287 
  
1.24(1.04-1.48) 
0.017 
  Female  1 1 
Age category  
  
  
  
  
18-25 1.3(1.06-1.59) 
0.003 
  
  
  
  
1.33(1.09-1.64) 
0.001 
  
  
  
  
26-35 1 1 
36-45 0.92(0.74-1.15) 0.91(0.73-1.13) 
46-55 0.69(0.5-0.97) 0.68(0.49-0.95) 
>55 0.83(0.47-1.49) 0.81(0.45-1.44) 
Clinic  
  
  
Metro 1  1 
0.225 
  
  
1 
0.076 
  
  
Metro 2  1.05(0.88-1.26) 1.23(0.98-1.55) 
Rural 1  0.86(0.68-1.1) 1.01(0.77-1.31) 
Baseline TB  Yes  0.95(0.54-1.68) 0.860 0.97(0.54-1.72) 0.913 
Previous ART of > 3 
months Yes  0.97(0.55-1.72) 0.921 1(0.56-1.77) 0.997 
Year ART start  
  
2014 0.81(0.67-0.97) 
0.024 
  
0.75(0.6-0.94) 
0.011 
  2015 1 1 
 
Analysis restricted to 1100 individuals with follow up >12months. Likelihood ratios were used to estimate P 
values in regression models where categorical variables had more than two strata. Model fits were assessed as 
good based on the likelihood ratio test statistic. Selection of baseline variable category for comparison (HR=1) 
was based on sample size and clinical significance. 
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  Figure1: Kaplan Meir failure estimates for attrition stratified by baseline CD4 cell count.  
 
  BLCD4: Baseline CD4 cell count in cells/µL. Log-rank test for equality of survivor functions: P=0.02 
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Chapter 5: Incidence of Tuberculosis amongst HIV-positive individuals 
initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 
(PopART) trial in South Africa 
 
Citation: Bock P, Jennings K, Vermaak R, Cox H, Meintjes G, Fatti G, et al. Incidence of 
Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher 
CD4 Counts in the HPTN 071 (PopART) Trial in South Africa. J Acquir Immune Defic Syndr. 
2018 Jan 1;77(1):93-101. 
 
Study design overview  
This study used the same cohort of 2423 individuals used in chapter 4 to evaluate the 
impact of HIV-positive individuals initiating ART a baseline CD4 count >500 cells/µL on TB 
incidence during early ART (Table 4). TB incidence, the primary endpoint, was defined as 
having been recorded as starting TB treatment after ART initiation in ETR.net. All individuals 
were followed up until the date of attrition, elective transfer to another facility (TFO), 
incident TB or end May 2016, whichever occurred first. Data was from the same sources as 
the study evaluating attrition presented in chapter 4 was used. This study addressed the 
following PhD objective:  
 
To evaluate the impact of routine initiation of ART at baseline CD4 counts >500 cells/µL at 
DOH ART clinics on TB incidence during early ART.  
Table 4: TB study outline  
Primary 
outcome 
Study site  Recruitment 
period 
Exclusion 
criteria  
Follow-up  Data sources  
Incident 
TB 
Three SA 
PopART Arm 
A clinics 
1 Jan 2014 
to end Nov 
2015 
Missing 
baseline CD4 
count  
Until 
attrition, 
TFO, Incident 
TB or end 
May 2016  
Tier.net, 
ETR.net and 
NHLS reports 
 
Author contribution: I was responsible for setting up the study cohort used for this study in 
partnership with DOH and PEPFAR implementing partners. I conceptualised this study with 
the senior authors (PB, GF, HC, NB) and completed the statistical analysis with support from 
SF and GF. All authors contributed toward development of the manuscript and reviewed 
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drafts, including the final version accepted by the journal. I was the corresponding author in 
submission and publication of the study. 
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Chapter 6: Renal dysfunction in a cohort of adults starting 
antiretroviral treatment at baseline CD4 counts >500 cells/µL in the 
HPTN 071 (PopART) study in South Africa.  
 
Unpublished: This study will be submitted to the HPTN 071 (PopART) publication review 
process in October/November 2017.  
 
Study design overview  
This study evaluated the impact of starting ART at baseline CD4 counts >500 cells/µL on 
incidence of renal dysfunction during early ART. Routine NHLS laboratory creatinine results 
were used to calculate EGFR levels which were used for measurement of the primary 
endpoint, incident renal dysfunction. Incident renal dysfunction was defined as an EGFR 
<60ml/min after ART initiation. The study used the same cohort of adults used in chapters 3 
and 4. All individuals were followed up until the date of attrition, elective transfer to 
another facility (TFO), incident renal dysfunction or end May 2016, whichever occurred first. 
In addition to the data sources used in chapters 3 and 4, missing EGFR data were extracted 
from clinic folders. This study addressed the following PhD objective:  
To evaluate the impact of routine initiation of ART at baseline CD4 counts >500 cells/µL at 
DOH ART clinics on the incidence of renal dysfunction during early ART 
 
Table 5: Renal dysfunction study outline  
Primary 
outcome 
Study site  Recruitment 
period 
Exclusion 
criteria  
Follow-up  Data sources  
Incident 
renal 
dysfunction  
Three SA 
PopART Arm 
A clinics 
1 January 
2014 to end 
November 
2015 
Missing 
baseline CD4 
count  
Until 
attrition, 
TFO, incident 
renal 
dysfunction 
or end May 
2016.  
Tier.net, 
ETR.net, NHLS 
reports and 
clinic folders  
 
Author contribution: I was responsible for setting up the study cohort used for this study in 
partnership with DOH and PEPFAR implementing partners. I, with support from senior authors 
(GF, NF, NB and SF), conceptualised this study. I completed the statistical analysis with 
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support from Sian Floyd (SF), Rosa Sloot (RS) and Geoffrey Fatti (GF). All authors contributed 
toward development of the manuscript and reviewed drafts including the final version 
included in this dissertation.  
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Renal dysfunction in a cohort of adults starting antiretroviral treatment at baseline CD4 
counts >500 cells/µL in the HPTN 071 (PopART) study in South Africa.  
Peter Bock1, Kerry Nel1,2, Geoff Fatti3, Rosa Sloot1, Nathan Ford4, , Sian Floyd5, Richard Hayes5, Helen 
Ayles6,  Nulda Beyers1 & Sarah Fidler7 on behalf of the HPTN 071 (PopART) team  
1: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of 
Medicine and Health Sciences, Stellenbosch University, South Africa 
2: City of Cape Town Health Services, Cape Town, South Africa 
3: Kheth’ Impilo, Aids Free Living, Cape Town, South Africa 
4. Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape 
Town, South Africa 
5. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical 
Medicine, London, UK 
6. Department of Clinical research, London School of Hygiene and Tropical Medicine, 
London, UK 
7. Department of Medicine, Imperial College London, London, UK.  
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Abstract  
Introduction 
Renal dysfunction is a significant cause of morbidity and mortality amongst HIV-positive 
individuals. This paper evaluates renal dysfunction in a cohort of adults starting 
antiretroviral treatment (ART) regardless of CD4 count at three department of health (DOH) 
clinics included in the HPTN071 (PopART) trial.  
 
Methods 
A retrospective cohort analysis of routine data of HIV-positive individuals starting ART 
between January 2014 and November 2015 was completed. Incident renal dysfunction was 
defined as an estimated glomerular filtration rate (EGFR) <60mL/min after ART initiation 
amongst individuals with a baseline EGFR ≥60mLmin. All participants were followed up from 
ART initiation until loss to follow-up, death, transfer out to another clinic or incident renal 
dysfunction, or until end May 2016; whichever occurred first.  
 
Results 
Overall 2423 individuals with a median baseline CD4 count of 328 cells/µL (IQR 195-468) 
were included in the analysis. Regression analysis showed lower odds of baseline 
EGFR<60mL/min at baseline CD4 counts of >500 cells/µL (aOR 0.29; 95% CI 0.11-0.80), 351-
500 cells/µL (aOR 0.22; 95% CI 0.08-0.59) and 201 to 350 (aOR 0.48; 95% CI: 0.24-0.97) 
when compared to baseline CD4 counts CD4 <200 cells/µL. Amongst individuals with 
baseline EGFR >60mL/min, there was no association between baseline CD4 count and 
incident EGFR<60mL/min. Analysis restricted to individuals with baseline EGFR ≥90mL/min 
showed no incident cases of EGFR<60mL/min amongst individuals with baseline CD4 counts 
>500 cells/µL.  
 
Conclusion  
This study showed lower rates of renal dysfunction amongst individuals with baseline CD4 
>200 cell/µL at the time of starting ART. The study also, promisingly, showed no incident 
renal dysfunction amongst individuals with normal baseline EGFR and baseline CD4 counts 
>500 cells/µL, although larger studies are required to confirm this finding. Strategies that 
incorporate risk matrices to guide more focused implementation of EGFR monitoring as part 
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of differentiated models of care may enhance EGFR monitoring and should be the subject of 
implementation research. 
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Introduction  
The number of individuals on antiretroviral therapy (ART) continues to increase annually. (1) 
Implementation of recent WHO recommendations of ART regardless of CD4 count in high-
burden settings will lead to an increased number of HIV-positive individuals starting ART at 
baseline CD4 counts >500 cells/µL. (2)  
 
Renal dysfunction is a well-recognised cause of morbidity and mortality amongst HIV-
positive individuals starting ART. (3, 4) Although immune reconstitution after ART initiation 
is overall associated with improved renal function, it may, conversely, be negatively 
impacted by toxicity of commonly used antiretrovirals, such as tenofovir. (3, 4)  In the 
absence of accessible alternative antiretrovirals, with superior renal toxicity profiles, 
tenofovir remains a drug of choice for first line ART in high burden settings. (2, 5, 6)  Routine 
monitoring of renal function in individuals starting tenofovir, by measurement of serum 
estimated glomerular filtration rate (EGFR), is recommended, and tenofovir is 
contraindicated in individuals with EGFR <50mL/min at the time of ART initiation.  
 
Programmatic studies from high-burden settings show varying baseline prevalence of renal 
dysfunction amongst individuals starting ART. (7-11). (7, 10). The reported association 
between baseline CD4 count and baseline renal dysfunction varies; with some studies 
showing higher baseline renal dysfunction at lower CD4 counts, (9, 10) and other studies 
showing no association. (7, 11)  
 
With respect to renal function after ART initiation, programmatic studies, with median 
baseline CD4 counts ranging from 154 to 209 cells/µL, show decreased renal dysfunction 
after ART initiation amongst individuals with baseline CD4 counts >200 cells/µL compared to 
lower values. (12, 13) Recently published results from the START trial showed higher mean 
EGFR after ART initiation amongst individuals starting ART at baseline CD4 counts >500 
cells/µL when compared to those with baseline CD4 350 to 500 cells/µL. (14) There are, 
however, limited data from programmatic studies to confirm these findings. In this context, 
the primary aim of this study was to evaluate the impact of routine initiation of ART at CD4 
counts >500 cells/µL on the incidence of renal dysfunction during early ART in a cohort of 
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adults starting ART regardless of CD4 at three Department of Health (DOH) clinics included 
in the HPTN 071 (PopART) trial, in South Africa.  
 
Study setting  
The HPTN 071 Population Effect of Antiretroviral Therapy to Reduce HIV Transmission 
(PopART) study is a community randomised trial currently being implemented in South 
Africa and Zambia. A full description of the PopART trial design is previously published. (15) 
For PopART, a community was defined as the catchment population of a DOH primary 
healthcare (PHC) clinic. PopART communities were randomly allocated to one of three arms: 
A, B or C. Arm A communities received the full intervention including community HIV 
prevention services delivered by a cadre of community workers named ‘CHiPs’ (‘Community 
HIV Care Providers’) and ART regardless of CD4 count at the local DOH clinic. Arm B 
communities received the CHiPs intervention with ART as per in-country guidelines, while 
Arm C communities received standard care interventions only.  
 
ART services at the three study clinics were provided according to provincial department of 
health (DOH) ART guidelines; (5) with the exception that all three study clinics provided ART 
regardless of CD4 count from 1 January 2014, before the provincial DOH ART guidelines 
changed to ART regardless of CD4 count in October 2016. (5) Routinely, all individuals 
starting ART are recorded in the electronic HIV program monitoring system, Tier.net, (16) A 
fixed-dose combination tablet of tenofovir, emtricitabine and efavirenz (TEE) was used as 
the first-line ART regimen of choice. All laboratory services were provided by the centralised 
regional National Health Laboratory Services (NHLS) with daily pick up of specimens from all 
PHC clinics. Tenofovir was contraindicated in clients with baseline EGFR <50 mL/min in 
whom zidovudine (AZT), stavudine (D4T) or abacavir (ABC) were recommended first-line 
alternatives. For individuals starting tenofovir, serum creatinine used for EGFR estimation 
was measured prior to ART initiation at 4 and 12 months after initiating therapy, and 
annually thereafter. (17)  
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Cohort overview and definitions  
A retrospective cohort study design was utilised. All HIV-positive adults (≥18years) recorded 
in Tier.net, (16) as having started ART at the three study clinics between 1 Jan 2014 and end 
November 2015 were screened for inclusion. Individuals were excluded from analysis if they 
did not have a recorded baseline CD4 count. All individuals were followed up for a minimum 
of six months until end May 2016 (the date of administrative censor) or until the date of 
attrition or transfer out (TFO), if that occurred earlier. For the analysis of incident renal 
dysfunction, as a binary variable, individuals were censored after the first episode of 
EGFR<60mL/min. 
 
Baseline CD4 was defined as the most recent CD4 completed in the six months prior to 
starting ART. Baseline EGFR was estimated from the most recent serum creatinine (SCR) 
completed in the six months prior to starting ART. American National Kidney Foundation 
criteria were used to define levels of renal dysfunction; mild (EGFR 60 - 89 mL/min), 
moderate (EGFR 30 - 59 mL/min) or severe (EGFR <30mL/min) to best align with other 
published data. (18) Moderate and severe renal dysfunction were combined (EGFR 
<60mL/min) for analysis of both baseline renal dysfunction (EGFR<60mL/min) and incident 
renal dysfunction (EGFR<60mL/min). Baseline TB was defined as being on TB treatment at 
the time of ART start. Attrition included all individuals no longer in care as a result of loss to 
follow-up (LTFU) or death. Attrition was defined as being three months late for a scheduled 
clinic appointment. Death and LTFU was not analysed separately in this study as death was 
not consistently recorded in Tier.net. Transfer out (TFO) was defined as elective transfer of 
an individual to another ART clinic documented in Tier.net.  
 
Data sources and management  
Routine DOH and National Health Laboratory Services (NHLS) data were used for this study. 
Unless otherwise stated all data were extracted from Tier.net. (16) Data on SCR results were 
extracted from the NHLS database and linked to Tier.net data using the DOH unique 
identifier. EGFR was calculated from SCR age and sex using the MDRD Study equation (EGFR 
= 175 × standardized SCR −1.154 × age−0.203 × 1.212 [if black] × 0.742 [if female], (19) with 
omission of the racial categorisation factor as recommended in previous publications. (13, 
20) Additional creatinine data, missing from the NHLS data extracts were, where available, 
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extracted from clinic folders. Data from the DOH electronic TB monitoring system, ETR.net, 
was used to identify individuals with baseline TB. All data fields and data linkages were 
reviewed for completeness and accuracy.  
 
Analysis  
Standard descriptive analyses including absolute numbers and proportions were used to 
describe baseline characteristics. Similarity of baseline characteristics across baseline CD4 
count categories was analysed using Chi-Square and Kruskal-Wallis tests. Logistic regression 
was used to model the association of other baseline characteristics with baseline renal 
dysfunction. Two way scatter and fitted line graphs were used to illustrate trends in EGFR 
over time on ART. Mixed effects linear regression was used to model the association of 
baseline characteristics with mean EGFR over time on ART. Time-to-event analyses of 
incident EGFR<60mL/min as a binary variable were completed using Kaplan-Meier survival 
estimates amongst individuals with baseline EGFR ≥60mL/min. Cox regression was used in 
analysis of baseline characteristics associated with hazard of EGFR<60mL/min on ART 
amongst individuals with baseline EGFR ≥60mL/min. Women pregnant at the time of 
starting ART were excluded from the analysis of baseline and on ART EGFR<60mL/min due 
to increases in EGFR levels during pregnancy of up to 50%. (21) 
 
The same baseline characteristics namely age, sex, CD4 count, EGFR, TB status, clinic where 
treatment was received, year when ART started, pregnancy at baseline and previous ART 
exposure of more than three months, were included in all multivariate models unless 
otherwise stated. Baseline characteristics for inclusion in multivariate modelling were 
selected based on clinical significance of available data. The reference category for 
categorical variables was selected by using the category with the largest sample size or on 
clinical significance. Comparison of baseline characteristics between individuals excluded 
from analysis due to missing results of baseline EGFR or EGFR after ART initiation and those 
retained in the analysis were completed using logistic regression. Logistic regression was 
also used to compare baseline characteristics of individuals retained in the study cohort and 
those experiencing attrition or TFO. Analyses were performed using Stata TM version 13 
(StataCorp LP, College Station, TX, USA). 
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Ethics  
The HPTN 071 (PopART) trial has been approved by the Stellenbosch University Health 
Research Ethics Committee (HREC) (Ref. No. N12/11/074) and the London School of Hygiene 
and Tropical Medicine research ethics committee (Ref no. 6326). All HIV-positive individuals 
starting ART outside of provincial ART guidelines signed informed consent. Additional HREC 
approval for the use of individual-level DOH data, including a waiver for informed consent, 
for the completion of this study was received from SU HREC (Ref no. N12/11/074A) as well 
as from the Western Cape Government (Ref no. WC_2015RP51_715) and City of Cape Town 
(Ref no 10529) research committees.  
 
Results 
Baseline characteristics  
Overall 2593 individuals were screened for study inclusion, 170 (6.6%) were excluded due to 
missing baseline CD4 cell counts leaving 2423 (93.4%) individuals included in the baseline 
analysis  (Table 1). Median baseline CD4 count was 328 cells/µL (IQR 195-468). The 
proportion of individuals across baseline CD4 cell categories varied between 631 (26.0%) at 
CD4 0-200 cells/µL and 502 (20.7%) at CD4 >500 cells/µL. Median age was 31 years (IQR 26-
38) and the majority (1661/67.9%) were women. Baseline EGFR was available for 2141 
(88.4%) of individuals with a reported baseline CD4 count. Median baseline EGFR was 110.5 
mL/min (IQR 93.5 - 131.9). A total of 47 (1.9%), 394 (16.3%) and 1700 (70.2%) individuals 
had baseline EGFRs <60 mL/min, 60-89 mL/min and ≥90 mL/min respectively. The number 
with EGFR <60 mL/min ranged from 24 (3.8%) at baseline CD4 count 0-200 cells/µL to 5 
(1.0%) at baseline CD4 counts >500 cells/µL (P<0.001).  
 
Analysis of baseline characteristics associated with baseline renal dysfunction.  
Univariate and multivariate logistic regression analysis of the association between baseline 
characteristics and baseline EGFR<60mL/min amongst the 2014 non-pregnant individuals 
with a reported baseline CD4 count are shown in table 2. The adjusted odds ratios (aORs) of 
baseline EGFR<60mL/min across baseline CD4 categories were 0.29 (95% CI 0.11-0.80) for 
CD4 counts >500 cells/µL, 0.22 (95% CI 0.08-0.59) for CD4 counts 351-500 cells/µL and 0.48 
(95% CI: 0.24-0.97) for CD4 counts 201 to 350 cells/mL when compared to CD4 0-200 
cells/µL. Baseline EGFR<60mL/min was also more common in individuals aged >35years with 
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aORs of 3.38(95% CI: 1.64-6.95) for ages 36-45 years and 6.40 (95% CI: 3.06-13.37) for ages 
>45 years when compared to individuals aged ≤35 years. Baseline EGFR<60mL/min was also 
more common amongst males (aOR = 1.99; 95% CI: 1.08-3.66) than amongst women. There 
were no other baseline variables associated with baseline EGFR<60mL/min. 
 
Analysis of renal function after ART initiation  
A total of 651 (26.9%) individuals were excluded from the analysis of EGFR after ART 
initiation for the following reasons: i) missing baseline EGFR (282 individuals/43.3%); ii) 
started on an ART regimen which did not contain tenofivir or unknown baseline ART 
regimen (53 individuals/ 8.1%) and iii) no reported EGFR after ART initiation (on ART EGFR) 
(316 individuals/48.5%). The remaining 1772 (73.1%) individuals were included in the 
analysis of EGFR after ART initiation (on ART EGFR) and were followed up for a median of 
12.1 (IQR 7.9-16.9) months, during which time 329 (18.6%) experienced attrition and 85 
(4.8%) experienced TFO.  
 
The mean EGFR on ART was 114mL/min (95%CI 113 -115). Changes in on?? ART EGFR are 
shown in figures 1a to 1d. Multivariate mixed effects linear regression showed that 
compared to those with baseline EGFR ≥90mL/min, mean on ART EGFR was 37.49 mL/min 
(95% CI 28.52-46.46) lower amongst individuals with baseline EGFR <60mL/min and 
22.47mL/min (95%CI 19.34-25.60) lower amongst individuals with baseline EGFR 60 to 89 
mL/min when. Mean on ART EGFR was 20.56mL/min (95%CI 15.57-25.55) greater amongst 
women pregnant at baseline and 6.80mL/min (95% CI 3.67-9.92) lower amongst individuals 
attending Metro 2 clinic compared to Metro 1. There was no difference in mean EGFR when 
comparing individuals treated at the rural clinic and Metro 1.  
 
For analysis of incident EGFR<60ml/min, 107 women pregnant at baseline were excluded 
from analysis of incident EGFR<60ml/min leaving a sample size of 1665. Kaplan Meier 
estimates showed higher rates of on? ART EGFR<60mL/min over time at lower baseline CD4 
counts (P<0.05) (Figure 2).  There were 33 incident cases of EGFR<60mL/min during 1749 
person years (PY), incidence rate (IR) 1.9/100PY (95%CI 1.3-2.6). The IR of EGFR<60mL/min 
amongst this group was highest during the first six months of ART (IR = 2.3/100PY (95% CI 
1.99-2.66) compared to longer duration of ART; however this difference was not statistically 
significant. Additional analysis further restricted to 1651 non-pregnant individuals with 
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baseline EGFR ≥60mL/min showed a lower IR of EGFR <60ml/min (1.6/100P:95%CI 1.1-2.3) 
(Table 4). When further restricting analysis to 1333 non pregnant individuals with EGFR 
≥90mL/min, there were only 15 incident cases of EGFR <60mL/min (IR = 1.1/100PY; 95% CI 
(0.6-1.8). Notably when limiting analysis to this group with normal baseline EGFR there were 
no incident cases of EGFR<60ml/min amongst individuals with baseline CD4 counts >500 
cells/µL.  
 
Multivariate Cox regression which included all 1651 non-pregnant individuals with baseline 
EGFR>/=60mL/min (Table 5) showed a lower hazard ratio of EGFR <60mL/min at higher 
baseline CD4 categories compared to baseline CD4 count <200cell/µL, but this finding was 
not statistically significant. There was a higher hazard of incident EGFR<60mL/min amongst 
individuals with baseline EGFR 60 to 89mL/min (aHR = 2.62; 95% CI 1.17-5.83) compared to 
those with baseline EGFR ≥90mL/min and amongst individuals aged >45 years (aHR 3.25; 
95% CI: 1.30-8.14) compared to individuals aged ≤35 years. No other baseline characteristics 
were associated with incident EGFR<60mL/min.  
 
 Analysis of missing data  
Logistic regression using the full model showed increased rates of missing baseline EGFR 
results at higher baseline CD4 counts >500 cells/µL (aOR = 1.54; 95%CI 1.04-2.26) compared 
to baseline CD4 counts ≤200 cells/µL. Individuals with missing baseline EGFR results were 
less likely to be men (aOR = 0.71; 95%CI 0.55-0.93) and more likely to attend the rural clinic 
(aOR = 1.54 95% CI: 10.01 -2.33) rather than Metro 1. Individuals excluded from follow-up 
analysis due to missing on ART EGFR were more likely to have a baseline CD4 count of 201 
to 350 cells/µL (aOR = 1.35; 95%CI 1.00-1.83). Individuals experiencing attrition or TFO were 
less likely to have started ART in 2015 (aOR = 0.60 95% CI: 0.46-0.79) as opposed to 2014; 
less likely to be aged 36-45 years (aOR = 0.72 95% CI: 0.55-0.97) or >45 years (aOR = 0.49 
95% CI: 0.33 0.72) as opposed to ≤35 years and more likely to be treated at Metro 2 clinic 
(aOR = 1.46; 95% CIs 1.09-1.95) rather than ato Metro 1.  
 
Discussion  
This is one of the first papers to evaluate the association between baseline CD4 count and 
renal dysfunction in a cohort of individuals routinely starting ART regardless of CD4 count in 
a high-burden programmatic setting. This study showed low baseline prevalence rate of 
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EGFR <60mL/min (1.9%) similar to a large published study from Zambia (22) Also similar to 
previous studies, (10, 13, 23) this study showed lower baseline prevalence of renal 
dysfunction at baseline CD4 counts >200 cells/µL and amongst older individuals. Notably, 
this study showed no significant difference in prevalence rate of baseline EGFR <60mL/min 
between different categories in individuals with baseline CD4 counts >200 cells/µL. 
Comparison of both the prevalence rate of baseline EGFR <60mL/min and the incidence of 
EGFR <60mL/min after ART initiation between this study and other published studies was 
hampered by extensive heterogeneity of definition for renal dysfunction across studies.  
 
The overall incidence rate of EGFR<60mL/min (1.9 cases/100PY) was lower than that 
reported in a previous study (5.9 cases/100PY) with a lower baseline median CD4 count that 
reported the same endpoint. (13) In contrast to previous studies, (7, 14) this study did not 
show an association between baseline CD4 count and average EGFR or renal dysfunction 
after ART initiation when adjusting for key baseline characteristics. Notably, analysis of 
incident EGFR <60mL/min -restricted to individuals with a normal baseline renal function- 
showed a low incidence rate of EGFR <60mL/min 1.1 cases/100PY (95% CI: 0.6-1.8) and no 
incident cases amongst individuals with baseline CD4 counts >500 cells/µL. As in previous 
studies, this study showed baseline renal dysfunction to be a very strong predictor of on 
ART renal dysfunction. (10, 13, 22)  
 
Overall the results of this study show a small decline in EGFR after ART initiation with low 
baseline prevalence and on ART incidence of EGFR<60mL/min in a cohort of individuals 
started on tenofovir. Monitoring of renal function in high-burden settings is challenging. (10, 
24) Tenofovir continues to be widely used for first line ART in high-burden regions and in the 
absence of an affordable alternative, strategies to improve EGFR monitoring in individuals 
on tenofovir are a priority  (2, 17) 
 
Tenofovir alafenamide (TAF) is a tenofovir prodrug, now available in the developed world, 
with reported lower risk of renal toxicity, (25, 26) and routine access to TAF in high-burden 
settings may greatly reduce the need for renal monitoring on ART. There are, however, 
concerns related to this approach, as TAF interacts with rifampicin used for TB treatment. 
Further research into its efficacy and safety in contexts with high rates of HIV and TB 
coinfection are required. (2, 27) 
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Despite a well-established ART service in the Western Cape since 2014, and the provision of 
ART regardless of CD4 count in the PopART intervention since January 2014, a significant 
proportion (26%) of this cohort presented with baseline CD4 counts <200 cells/µL. These 
data suggest that ART regardless of CD4 count, with increased numbers of individuals 
starting ART at higher CD4 counts, will have a positive impact on baseline renal function 
amongst individuals starting ART, and interventions to reduce the number of individuals 
starting ART late at low CD4 counts should be further strengthened. Although these data did 
not show an association between baseline CD4 count and renal dysfunction in the primary 
analysis, the absence of incident renal dysfunction amongst individuals with baseline CD4 
>500 cells in analysis restricted to individuals with normal baseline renal function, is 
promising and should be further evaluated in larger studies.  
 
Management of renal function on ART is further challenged by limited access to laboratory 
services in resource-limited settings and further research to evaluate the potential of more 
accessible of point of care technology for monitoring renal function are urgently needed. 
(24) In settings where relevant laboratory services are available, non-adherence to EGFR 
monitoring is widely reported. (24) Development of risk matrices for renal dysfunction 
amongst individuals starting ART to guide more focused implementation of EGFR monitoring 
as part of differentiated models of care may be an effective approach to improving EGFR 
monitoring, (28) and should be the subject of implementation research. 
 
Strengths and weaknesses  
This study presents high-quality routine data from three clinics providing ART regardless of 
CD4 count, ahead of recent changes in WHO and in-country ART guidelines. The routine 
data used also benefited from data quality improvement interventions during the PopART 
intervention. The study has been a joint undertaking between researchers and clinical staff 
ensuring that the analysis and interpretation of the data correctly reflect clinical activities. 
The study does, however, have a number of weaknesses for consideration. There were 
significant amounts of missing data and attrition from ART care. Individuals excluded 
because of missing baseline EGFR were more likely to have baseline higher CD4 counts and 
inclusion of these individuals in the study sample could have resulted in decreased rates of 
renal dysfunction being reported. Individuals experiencing attrition or TFO were more likely 
to be aged <35 years which may have exaggerated the observed lower renal dysfunction in 
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these age groups seen in the multivariate analyses. Extrapolation of these findings is also 
decreased by limited follow-up person time with several findings, such as the association 
between baseline CD4 count and incident EGFR<60mL/min, of borderline statistical 
significance.  
 
Conclusion  
In conclusion, this study showed lower prevalence of baseline EGFR<60mL/min at higher 
CD4 counts and no association between baseline CD4 count and incident on ART EGFR<60 
mL/min. Overall incidence of EGFR<60ml/min on ART was low;  analysis restricted to 
individuals with normal baseline EGFR, however, promisingly showed no incident on ART 
EGFR<60mL/min amongst individuals with baseline CD4 count >500 cells/µL. Differentiated 
models of care that identify individuals starting ART, who are at high risk of renal 
dysfunction, for enhanced EGFR monitoring and alternative ART regimens may be more 
effective than the current one size fits all approach. At the same time improved access to 
suitable affordable alternatives to tenofovir, should be further evaluated in high-burden 
settings.  
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Tables and figures  
Table 1: Baseline characteristics  
   
cells
/µL 0 to 200 201 to 350 351 to 500 >500 Total P value  
Baseline CD4 
category   
N(%)  631 (26.0)  708 (29.2)  582 (24.0) 502 (20.7) 2423   
Age (Years)  Median 
 
(IQR)  
33  
(29.0-40.0) 
 31 
(25.0-37.0) 
31  
(26.0-37.0) 
 30 
(25.0-37.0) 
 31 
(26.0-38.0) <0.001  
Age category 
(years) 
  
  
  
  
18-25 
N(%)  79 (12.5) 179 (25.3) 142 (24.4) 134 (26.7) 534 (22.0) <0.001  
26-35 
N(%)  312 (49.6) 311 (43.9) 272 (46.7) 227 (45.2) 1122 (46.3)   
36-45 
N(%)  167 (26.5)  138 (19.5) 109 (18.7) 87 (17.3) 501 (20.7)   
46-55 
N(%)  57 (9.0)  63 (8.9) 46 (7.9) 44 (8.8) 210 (8.7)   
>55 
N(%)  17 (2.7)  17 (2.4) 13 (2.2) 10 (2.0) 57 (2.3)   
Gender 
  
Female  
N(%)  
361 (56.4) 467 (65.4) 425 (72.5) 408 (80.5) 1661 (67.9) P<0.001  
Male  
N(%)  
279 (43.6) 247 (34.6) 161 (27.5) 99 (19.5) 786 (32.1)   
Pregnant at 
ART start  Yes 
N(%)  14 (3.9)  39 (8.4) 41 (9.7) 48 (11.9) 142 (8.6) P<0.001  
Baseline TB  Yes  
N(%)  162 (25.7)  56 (7.9) 41 (6.7) 26 (5.2) 285 (11.8) P<0.001  
Clinic  
  
  
Metro 1  
N(%)  88 (13.9)  113(15.9) 126 (21.7) 127 (25.3) 454 (18.7) P<0.001  
Metro 2  
N(%)  299 (47.4)  301 (42.5) 231 (39.7) 191 (38.1) 1022 (42.2)   
Rural 1  
N(%)  244 (38.7)  294 (41.5) 225 (38.7) 184 (36.7) 947 (39.1)   
Previous 
ART>3mths  Yes 
N(%)  27 (4.3)  10 (1.4) 7 (1.2) 5 (1.0) 49 (2.0) P = 0.005 
ART start 
year  
  
2014 
N(%)  161 (25.5)  208 (29.4) 160 (27.5) 161 (32.1) 690 (28.5) P = 0.091 
2015 
N(%)  470 (74.2) 500 (70.6) 422 (72.5) 341 (67.9) 1733 (71.5)   
Baseline 
EGFR 
(mL/min)  
  
 
 
 
 
 
 Median 
 
(IQR)  
 
106.7 
(89.5-130.6) 
110.6 
(94.3-129.7) 
111.1 
(93.1-131.7) 
112.9 
(96.5-134.1) 
110.5 
(93.5-131.9) 
P = 
0.0186 
<60 
N(%)  
24 (3.8) 14 (1.9) 4 (0.7) 5 (1.0) 47 (1.9) <0.001  
60 - 89  
N(%)  
114 (18.1) 106 (14.9) 100 (17.2) 74 (14.7) 394 (16.3)  
>90 
N(%)  
399 (63.3) 56 (71.4) 418 (71.8) 377 (75.1) 1700 (70.2)  
Missing  
N(%) 
93 (14.8) 83 (11.7) 60 (10.3) 46 (9.2) 282 (11.6)  
          
*This table includes all 2423 participants included in the study sample. Chi squared and Kruskal Wallis tests 
were used to measure heterogeneity of baseline characteristics across the baseline CD4 categories Overall 
there is significant heterogeneity across baseline CD4 categories. *** American  Kidney Foundation  definitions 
were used for defining renal function by EGFR. EGFR <60 mL/min = Moderate and severe renal dysfunction) 
EGFR 60 to 89 mL/min= Mild renal dysfunction EGFR >90 mL/min = Normal renal function 
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Table 2: Logistic regression of baseline characteristics association with baseline EGFR <60mL/min  
   Crude odds ratio (95% CI)  Adjusted odds ratio (95% CI)  
Baseline CD4  
(cells/µL)  
>500 0.19 (0.07-0.56) 0.29 (0.11-0.8) 
351-500 0.17 (0.06-0.47) 0.22 (0.08-0.59) 
201-350 0.38 (0.18-0.83) 0.48 (0.24-0.97) 
101-200 1 1 
Gender  Male  2.99 (1.68-5.34) 1.99 (1.08-3.66) 
Female  1 1 
Age at ART start 
(years)  
18-35 1 1 
36-45 4.14 (2.04-8.41) 3.38 (1.64-6.95) 
>45 7.39 (3.59-15.21) 6.40(3.06-13.37) 
Clinic  Metro 1  1 1 
Metro 2  1.68 (0.87-3.25) 1.96 (0.93-4.11) 
Rural 1.68 (0.76-3.69) 1.84 (0.77-4.39) 
Baseline TB  TB 1.55 (0.84-2.88) 0.97 (0.5-1.87) 
 
Previous 
ART>3mths  
Yes 
 1.03 (0.14-7.64) 0.86 (0.11-6.68) 
 
Year of ART start  ART2014 
 
 
 
ART2015 1.08 (0.59-2.00) 1.21 (0.59-2.48) 
Includes 2014 non-pregnant, individuals with recorded baseline CD4 count and baseline EGFR. Women 
pregnant at baseline were excluded due to changes in EGFR associated with pregnancy. Age category 18 to 25 
and 26 to 35 were combined and age category 46 to 55 and >55 were combined for the regression analysis due 
to collinearity between age categories 18 to 25 and >55 years with the dependant variable.  
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Figures 1a to 1d: Two way scatter plots of EGFR mL/min over time on ART  
(.Estimated EGFR         Fitted values)  
 
 
Figure 1a: All participants                   Figure 1b: Participants with baseline EGFR  
                     ≥90mL/min 
 
 
 
 
 
 
 
 
 
Figure 1c: Participants with baseline       Figure 1d: Participants with  
EGFR 60 to 89 mL/min                       baseline EGFR <60mL/min 
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Table 3: Mixed effects linear regression of mean on ART EGFR  
Estimated EGFR    
Crude coefficient 
(95% CI)  
Adjusted coefficient 
(95% CI)  
Baseline CD4  
(cells/µL)  
  
  
  
>500 2.72(-1.3-6.74) -0.79(-4.38-2.8) 
350 - 500 1.94(-1.93-5.81) -0.13(-3.56-3.29) 
200 - 350 1.28(-2.4-4.97) -0.17(-3.42-3.08) 
0 - 200  1 1 
Baseline EGFR (mL/min)  
  
  
<60 -27.08(-30.26 to-23.91) -37.49(-46.46 to-28.52) 
60 - 90 -44.46(-53.74 to-35.17) -22.47(-25.60 to-19.34) 
>90  1 1 
Gender  
  
Male  -4.65(-7.57 to-1.73) 1.27(-1.42-3.96) 
Female  1 1 
Age category (years)  
  
  
  
18-35 1 1 
36-45 -22.35(-26.48 to-18.22) -10.3(-13.36 to-7.25) 
>45 25.99(20.51-31.47) -13.3(-17.22 to-9.38) 
Pregnant at baseline Yes  25.99(20.51-31.47) 20.56(15.57-25.55) 
  
Clinic  
  
Metro 1  1 1 
Metro 2  -7.43(-10.45--4.4) -6.80(-9.92 to-3.67) 
Rural 1  -2.15(-5.77-1.48) -2.09(-5.69-1.52) 
Baseline TB  Yes  1.67(-1.63-4.97) -6.71(-17.38-3.96) 
Previous ART of  
>3 months Yes  -10.44(-22.63-1.75) 2.45(-0.52-5.42) 
Year ART start  
  
2014 1 1 
2015 2.29(-0.56-5.13) -1.67(-4.68-1.35) 
Months on ART   -0.36(-0.51 to-0.21) -0.36(-0.52 to-0.2) 
Modelling includes 1772 individuals with reported baseline and on ART EGFR including pregnant women.  
The individual unique identifier was used as the panel variable. For categorical variables the coefficient 
represents the difference in mean EGFR in mL/min from baseline compared to the reference category. 
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Figure 2: Kaplan Meier estimates of EGFR<60mL/min on ART in participants with baseline EGFR ≥  
60mL/min 
  
  Includes 1651 individuals with baseline EGFR ≥60mL/min Log rank test for difference in KP estimates  
  by CD4 category: P= 0.011 
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Table 4: Incident EGFR<60mL/min on ART amongst by baseline EGFR category  
 Baseline CD4 
count 
(cells/µL) 
 
All baseline  
EGFR 
Baseline 
EGFR≥60mL/min 
Baseline  
EGFR≥90mL/min 
Sample size  N  1665 1651 1401 
Number of 
incident cases 
 
N  33 27 15 
Person Years  PY 1749 1722 1421 
IR  0 to 200 3.8 (2.3-6.2) 3.2 (1.8-5.5) 2.5 (1.2-4.9) 
 201 to 350 1.6 (0.9-3.1) 1.1 (0.5-2.5) 0.9 (0.3-2.4) 
 301-500 0.9 (0.4-2.5) 0.9 (0.4-2.5) 0.9 (0.3-2.7) 
 >500 1.1 (0.4-2.9) 1.1 (0.4-3) 0 (0-0) 
 All  1.9 (1.3-2.6) 1.6 (1.1-2.3) 1.1 (0.6-1.8) 
PY: Person Years. IR: Incidence rate. Baseline EGFR cut offs were selected to align to American Kidney 
Foundation definitions; EGFR≥60mL/min= normal EGFR or mild renal impairment and EGFR≥90mL/min = 
normal renal function. 
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Table 5: Cox regression of baseline factors associated with incident EGFR <60mL/min on ART 
amongst individuals with baseline EGFR >/=60 mL/min 
    
Crude hazard ratio 
(95%CI)  
Adjusted hazard 
ratio  
(95% CI)  
Baseline CD4  
 
>500 0.36(0.12-1.11) 0.41(0.13-1.3) 
  
  
351 - 500 0.3(0.1-0.92) 0.35(0.11-1.1) 
201 - 350 0.35(0.13-0.93) 0.38(0.14-1.03) 
0 - 200 1 1 
 Baseline EGFR (mL/min)  
  
60 - 89 3.46(1.62-7.39) 2.62(1.17-5.83) 
>90  1 1 
Gender  
  
Male  1.46(0.68-3.15) 1.08(0.48-2.42) 
Female  1 1 
Age category(years)  
  
  
18 - 35  1 1 
36 - 45 1.63(0.61-4.35) 1.24(0.46-3.39) 
>45 4.33(1.83-10.29) 3.25(1.30-8.14) 
Clinic  
  
  
Metro 1  1 1 
Metro 2  0.86(0.37-2.01) 0.74(0.26-2.12) 
Rural 1  0.74(0.25-2.17) 0.68(0.19-2.39) 
Baseline TB  Yes  1.61(0.7-3.67) 1.27(0.54-3.04) 
Previous ART of >3 
months Yes  3.2(0.43-23.61) 1.77(0.23-13.77) 
Year ART start  
  
2014 1 1 
2015 1.07(0.47-2.44) 0.89(0.31-2.57) 
Non pregnant Individuals with baseline EGFR<60mil/min were excluded from analysis and the model includes 
1651 individuals with reported baseline EGFR>/= 60 mL/min. Women pregnant at baseline were excluded due 
to changes in EGFR associated with pregnancy. The multivariate model showed good fit (P<0.001). The 
baseline category with the largest sample size was used as the reference. There were no incident 
EGFR<60mL/min cases amongst individuals reported pregnant at baseline therefore this data variable was 
omitted from regression analysis. Age categories 46 to 55 years and >55 years were combined as >45 years 
due to limited sample size. 
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Chapter 7: Baseline CD4 Count and Adherence to Antiretroviral 
Therapy: A Systematic Review and Meta-Analysis.  
 
Citation: Bock P, James A, Nikuze A, Peton N, Sabapathy K, Mills E, et al. Baseline CD4 Count 
and Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. J Acquir 
Immune Defic Syndr. 2016 Dec 15;73(5):514-21. 
 
Study design overview  
This study was a systematic review and meta-analysis that evaluated the association between 
baseline CD4 count and ART adherence in published research studies. The study was 
completed according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement. For completion of the study we reviewed all English language 
journal articles, published between January 2004 and September 2015, listed in Medline, 
Web of Science, LILACS, AIM, IMEMR and WPIMR databases; as well as available conference 
presentations from key HIV conferences published between 2012 to 2015. The study 
addressed the following PhD objective:  
To evaluate through completion of a systematic review and meta-analysis of published   
literature the association between baseline CD4 count and adherence to ART.  
Table 6: ART adherence systematic review outline  
Primary 
outcome 
Study design Review period Primary inclusion 
criterion 
Data sources 
ART 
adherence 
Systematic 
review of 
published 
literature 
English language 
studies published 
between January 
2004 and 
September 2015. 
Conference 
abstracts published 
from 2012 to 2015. 
Studies that 
reported directly 
on the association 
between baseline 
CD4 count and 
ART adherence 
Medline, Web of 
Science, LILACS, AIM, 
IMEMR and WPIMR 
databases as well as 
available conference 
presentations from 
key HIV conferences 
 
Author contribution  
I conceptualised the design of this systematic review and meta-analysis in partnership with 
NF. I was responsible for the primary review of the literature which was then duplicated by 
AN, and/or AJ. I worked with NF to complete the statistical analysis. I coordinated 
development and finalisation of the manuscript for journal submission and publication. All 
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authors have contributed to development of the manuscript and have approved the version 
accepted for publication. 
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Chapter 8: Discussion  
 
This chapter provides an overview of the results of the studies contributing to this PhD 
dissertation. For each study, the results are discussed in the context of the published 
literature; the strengths and limitations of the study are also discussed. This discussion 
chapter also highlights how study findings, when combined with the findings of other 
studies, can strengthen the evidence base for HIV treatment services in high-burden 
settings. The chapter further discusses possible steps to address gaps in knowledge, health 
systems infrastructure, access to drugs and technology and models for the delivery of PHC 
services identified during the completion of the research.  
 
8.1 PhD dissertation overview  
The aim of this PhD dissertation was to evaluate the accuracy of household-based HIV point 
of care testing and the impact of routine provision of antiretroviral therapy (ART) on 
attrition, TB, renal dysfunction and ART adherence after ART initiation in HIV positive adults, 
at baseline CD4 counts >500 cells/µL. Overall, the findings from the studies in this 
dissertation are likely to be of high relevance to programme implementers in high-burden 
settings.  
 
8.2 Study evaluating HIV point of care testing (POCT) accuracy  
8.2.1 HIV POCT study findings  
The study presented in chapter 3, ‘Understanding low sensitivity of community-based HIV 
rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa’, 
evaluated the accuracy of household HIV POCT within the PopART population cohort (PC).  
 
Key findings of the study included low initial HIV POCT sensitivity in South Africa (45-54%), 
with improvement in sensitivity over time when implementing rigorous quality assurance 
(QA) of HIV POCT activities and quality control (QC) of HIV POCT kits. Sensitivity in Zambia 
during the same time period was significantly better (95.8%). There were some differences 
in the manner in which HIV POCT was conducted in Zambia and South Africa during the 
study period, to which this difference in sensitivity may be attributable. In Zambia, Alere 
Determine™ HIV-1/2 was used as the HIV screening test, during sequential HIV POCT, 
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throughout the study period. In South Africa, until September 2015, when sites also 
changed to using Alere Determine™ HIV-1/2 for screening as part of a sequential algorithm, 
First Response™ HIV 1-2-0 Card Test and SD Bioline HIV-1/2 3.0 were used for screening. The 
Zambian sites also conducted more rigorous QA/QC from the start of the study period, 
which included panel testing of HIV POCT test kits and proficiency testing of individuals 
conducting HIV POCT. In contrast, in South Africa, panel and proficiency testing were only 
introduced from January 2015. A further interesting finding in the study was a trend toward 
known HIV-positive individuals, some on ART, not disclosing their HIV status to PC staff and 
accepting HIV POCT: a scenario in which, the HIV POCT sensitivity might have been 
decreased by ART exposure. (1)  
 
8.2.2 HIV POCT study findings in context  
Household-based HIV POCT services have been shown to be an effective component of 
community-based HIV testing strategies (HTS), increasing the identification of HIV-positive 
individuals, including amongst high-risk, difficult-to-access groups, such as men. (2-4)  This 
study, however, highlighted the potential for low HIV POCT sensitivity in community settings 
and the need for rigorous HIV POCT QA/QC. Published HIV POCT sensitivity data from South 
African studies completed in both clinic and community settings ranges from 68 to 98%. (5, 
6) Encouragingly, however, a recent systematic review found overall low rates of HIV POCT 
false negative results (0.4%) in community settings in comparable high-burden settings. (5) 
Furthermore, the systematic review identified ‘remediable’ factors, such as user error, as 
the most significant contributors to decreased test accuracy. (7) At the same time, new HIV 
POCT kits with increased sensitivity for HIV antigen, such as the Alere™ HIV Combo assay 
(not used in PopART), may increase HIV POCT sensitivity in community-based settings and 
need further evaluation. (8) There remains limited published data reporting on the accuracy 
of household-based HTS. Completion of further operational research on this topic should be 
a priority. The finding that some individuals on ART were not disclosing their treatment 
status and were being retested for HIV should be a specific focus area for research.  
 
HTS coverage in high-burden settings remains well below global targets. (9, 10) In addition 
to strengthening existing HTS strategies, there remains an urgent need for new innovative 
strategies that target specific population groups that are at high risk of HIV infection and 
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difficult to access. In high-burden settings, these groups often include men, women aged 15 
to 24 and sex workers. (11, 12) Routine provision of oral HIV self-testing (13, 14) may be 
effective in increasing HTS coverage in high-burden settings, and may assist in reaching the 
high HTS coverage targeted by global agencies. (9) 
 
8.2.3 Strengths and limitations of the HIV POCT study  
The PopART trial provided a unique opportunity to evaluate the accuracy of HIV POCT in a 
field setting, through parallel HIV testing of individuals with HIV POCT and 4th-generation 
laboratory assays. There were, however, some limitations to the generalisability of these 
findings. Although the PopART sites were selected according to standardised criteria and we 
believe the sites included in PopART to be representative of the areas in which the trial is 
being completed, there was some non-adherence to these criteria in the ultimate selection 
of the PopART sites as the result of some eligible sites not being included in PopART. 
Reasons for this non- inclusion included being over burdened with prior research studies 
and relevant clinic management staff not wanting to be part of the trial.  When data were 
stratified, by annual quarter and country, sample sizes were small with low precision of 
sensitivity estimates. The study also did not directly analyse the association between factors 
potentially associated with HIV POCT sensitivity. These factors included choice of HIV POCT 
kit, extent of QA/QC implementation, variation between individual PC staff members (user 
error) and ART exposure. Furthermore, testing by the PopART PC teams only included 
individuals aged 18 to 45 years and HIV POCT was conducted by professional nurses as a 
component of a complex research intervention. Household-based HIV POCT is not yet 
standard care in most high-burden settings, but it is likely that the manner in which it will be 
conducted will differ from that used for PopART. These differences may include using a 
different cadre of staff, such as lay counsellors, and targeting a wider population group.  
 
8.3 Studies that evaluated the association between baseline CD4 count and 
attrition, TB incidence and renal dysfunction during early ART 
The studies presented in chapters 4 to 6 used routine data from a cohort of adults initiating 
ART at the three DOH PHC clinics included in Arm A of the PopART trial in South Africa.  
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8.3.1 Attrition during early ART study findings  
The study presented in chapter 4, ‘Attrition when providing antiretroviral treatment at CD4 
counts >500 cells/µL at three government clinics included in the HPTN 071 (PopART) trial in 
South Africa’, evaluated the impact of routine initiation of ART at baseline CD4 counts >500 
cells/µL at DOH clinics on attrition during early ART. Attrition included individuals no longer 
retained in care, due to both loss to follow-up or death, and was defined as being three 
months late for a pharmacy pick-up appointment. Overall, the study showed high 
cumulative attrition during the first 24 months on ART (26.2%), with increased attrition 
amongst individuals starting ART at CD4 counts >500 cells/µL, both when compared to 
individuals with baseline CD4 counts of 0-500 cells/µL (aHR 1.28, 95%CI 1.07 to 1.55) and 
when compared to individuals with baseline CD4 counts of 351-500 cells/µL (aHR 1.42, 95% 
CI 1.12-1.79).  
 
8.3.2 Attrition study findings in context  
Attrition from ART care is strongly associated with subsequent increased viral load. (15) As 
high-burden countries strive to attain universal access to ART, rapidly increasing ART 
coverage, while maintaining quality of care, will become increasingly challenging. (16) A 
wide range of strategies have been shown to be effective in improving retention in ART 
programmes; (17) however, despite this, attrition from ART programmes in high-burden 
settings is high. (18) In addition, there is a reported trend toward increased attrition as the 
number of individuals treated at PHC clinics increases and clinics become more congested. 
(19, 20) This trend is particularly concerning when considered in the context of the rapid 
scale-up of ART required to reach global targets in high-burden settings.  
 
Differentiated models of care that move away from the ‘one size fits all’ approach to ART 
service delivery, (21-23) may assist in improving retention in ART care. These differentiated 
models of care can include development of risk matrices used to identify individuals at high 
risk for attrition, such as the individuals with higher baseline CD4 counts identified in this 
study, for increased clinic and community support. At the same time, there can be referral 
of selected clinically stable individuals to clinic or community-based ART clubs, where they 
are managed in groups, helping to decongest overcrowded PHC clinics. (24)  Early studies 
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have shown improved or comparable clinical outcomes when implementing clinic or 
community-based ART clubs compared to clinic care. (22, 23) There remains, however, a 
lack of research evidence on how best to structure and manage ART clubs, as well as the 
cost-effectiveness of this approach.  
 
8.3.3 TB incidence during early ART study findings  
The study presented in chapter 5, ‘Incidence of Tuberculosis amongst HIV-positive 
individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 
(PopART) trial in South Africa’, evaluated the impact of routine initiation of ART at baseline 
CD4 counts >500 cells/µL at DOH clinics on TB incidence during early ART. Incident TB was 
defined as being recorded in the electronic TB register (ETR.net) as starting TB treatment 
after ART initiation. The study showed significantly lower TB incidence among individuals 
with baseline CD4 counts >500 cells/µL compared to those with baseline CD4 counts 0 to 
500 cells/µL (aHR = 0.27; 95% CI 0.12 to 0.62). These results were confirmed by a sensitivity 
analysis in a subset of individuals, which used bacteriologically confirmed TB as the primary 
endpoint. Furthermore, the study showed no incident TB in the first three months on ART 
among individuals with baseline CD4 counts >500 cells/µL; although the sample size in this 
group was relatively small, this finding may suggest a reduction in TB-associated IRIS, (25) 
among individuals whose CD4 count has never dropped below 500 cells/µL. The impact of 
isoniazid prophylaxis (IPT) on TB incidence was not reported in this study, as there were very 
high rates of missing data reporting on IPT provision in ETR.net.  
 
8.3.4 TB study findings in context  
TB remains the most common cause of death among HIV-positive individuals in high-burden 
settings. (26) These findings confirm, in a programmatic setting, the potential for routine 
initiation of ART at CD4 counts >500 cells/µL to reduce TB incidence amongst individuals on 
ART, which was previously demonstrated in randomised controlled trials (RCTs). (27, 28) 
Differentiated models of care may also be used to improve TB-related outcomes on ART. 
(29) Known risk factors, such as baseline CD4 count as illustrated in this study, can be used 
to generate risk matrices that identify individuals at high risk of TB on ART for more 
intensive screening after ART initiation. Risk matrices can also be used to identify individuals 
at high risk of TB at the time of ART initiation, for more intensive TB diagnostic screening 
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prior to ART initiation; screening could contribute to improved TB diagnosis at the time of 
ART initiation and improved TB-related outcomes on ART. (29, 30)  
 
Reductions in TB incidence among HIV-positive individuals on ART may also contribute to 
reductions in TB incidence at the population level. (31, 32) IPT has been shown to be 
effective in reducing TB incidence in HIV-positive individuals with positive tuberculin skin 
test (TST) results. (27, 33, 34) IPT implementation and monitoring in high-burden settings is, 
however, highly challenging, and to date, in South Africa, IPT has been poorly implemented. 
(27, 35) The need for TST prior to IPT provision and concerns about INH resistance are 
thought to have contributed to low uptake of IPT. (35, 36) The need for TST prior to IPT is 
debatable; (35) TST is more accurate in HIV-positive individuals with higher CD4 counts. (34) 
Recent changes to ART guidelines, with more individuals starting ART at higher CD4 counts, 
may strengthen the argument for TST before IPT provision and should be an important 
consideration in the ongoing debate on how best to improve IPT implementation.  
 
8.3.5 Incidence of renal dysfunction during early ART study findings  
The study presented in chapter 6, ‘Renal dysfunction in a cohort of adults starting 
antiretroviral treatment at baseline CD4 counts >500 cells/µL in the HPTN 071 (PopART) 
study in South Africa’, evaluated the impact of routine initiation of ART at baseline CD4 
counts >500 cells/µL on the incidence of renal dysfunction during early ART. Incident renal 
dysfunction was defined as an estimated glomerular filtration rate (EGFR <60mL/min) 
amongst individuals with baseline EGFR ≥60mL/min. In this study, baseline CD4 was not 
associated with incident renal dysfunction or mean EGFR on ART. Other baseline factors, 
including age >45years and baseline mild renal dysfunction (EGFR 60 to 89mL/min)  were, 
however, strongly associated with both higher average EGFR and higher incident renal 
dysfunction. When analysis of incident renal dysfunction on ART was restricted to 
individuals with normal baseline EGFR (EGFR ≥90ml/min), there were no cases of incident 
renal dysfunction amongst individuals with baseline CD4 >500 cells/µL. Analysis of factors 
associated with baseline moderate or severe renal dysfunction (EGFR <60ml/min) was also 
completed. This analysis showed a decreased prevalence of baseline moderate or severe 
renal dysfunction amongst individuals with baseline CD4 counts >500 cells/µL (aOR 0.29; 
95% CI 0.11-0.80), 351-500 cells/µL (aOR 0.22; 95% CI 0.08-0.59) and 201 to 350 (aOR 0.48; 
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95% CI: 0.24-0.97) when compared to baseline CD4 counts CD4 <200 cells/µL.  The baseline 
analysis also showed significantly higher baseline moderate or severe renal dysfunction 
amongst individuals of 36 to 45 years (aOR = 3.30; 95% CI: 1.60-6.77 and >45 years (aOR = 
6.32; 95% CI: 3.03-13.22) when compared to individuals ≤35 years old. 
 
8.3.6 Renal dysfunction study findings in context  
This programmatic study evaluating renal dysfunction after ART initiation, in the context of 
ART regardless of CD4 count, in high-burden regions, showed some important findings. The 
finding of no incident cases of renal dysfunction amongst individuals with normal baseline 
renal function, starting ART at baseline CD4 counts >500cel/µL, is novel and needs to be 
confirmed in other settings. The absence of an association between baseline CD4 
>500cells/µL and mean ‘on ART’ EGFR contrasts with results from the START trial, which 
showed a modestly improved mean EGFR amongst individuals starting ART at baseline CD4 
counts >500 cells/µL. (37) The lower prevalence of baseline renal dysfunction amongst 
individuals with higher CD4 counts at ART initiation reported in this study concurs with 
previously published data. (38) The higher rates of renal dysfunction amongst older 
individuals, both at the time of starting ART and while on ART, reported in this study are also 
supported by previous studies. (39-41) Comparison of the results of this study to other 
published data, however, was limited by heterogeneity in study methods, particularly in 
relation to the definitions of incident renal dysfunction on ART. (41, 42) 
 
Laboratory-based EGFR monitoring is recommended for individuals receiving tenofovir, a 
drug commonly used for first-line ART in high-burden settings. (43, 44) EGFR monitoring is 
often challenging, particularly in settings where the necessary laboratory equipment may be 
permanently or intermittently unavailable. (45) Baseline characteristics, such as older age 
and low BMI amongst individuals starting ART, have consistently been identified as risk 
factors for renal dysfunction after ART initiation. (39, 40) These proven risk factors for renal 
dysfunction could be used to identify high-risk individuals for more focused renal monitoring 
at baseline and after ART initiation. In addition further research is required to evaluate the 
more effective use of more accessible POCT tests such as urine dipsticks for proteinuria into 
simplified, renal monitoring algorithms (45, 46.)Improved routine access in high-burden 
settings to tenofovir alafenamide (TAF), a tenofovir prodrug with lower risk of renal toxicity, 
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(47, 48) may reduce the need for renal monitoring on ART. There are, however, concerns 
regarding the use of TAF in settings with high rates of HIV and TB coinfection. TAF interacts 
with rifampicin used for first-line TB treatment, and further investigation into its efficacy 
and safety in these contexts is urgently required. (44, 49) 
 
8.3.7 Strengths and limitations of the studies that evaluated the association between 
baseline CD4 count and attrition, TB incidence and renal dysfunction during early ART 
The studies presented in chapters 4 to 6 addressed topics of high public health importance 
and have resulted in some important findings. These were also some of the first studies to 
report on the provision of household-based HIV POCT and ART regardless of CD4 count in a 
programmatic setting. A further strength of these studies was the use of high-quality 
routine data, prospectively improved by health system strengthening activities linked to the 
PopART trial. As discussed with reference to the HTS study although there was some non-
adherence to the site selection process, we believe the PopART sites in which these studies 
were completed to be representative of high burden urban and peri-urban areas in the 
Western Cape. The studies were also completed in close partnership with DOH and PEPFAR 
implementing partners, who were, directly, involved in the provision of clinic services and in 
the development and quality control of relevant routine data systems, which greatly 
enhanced the accurate understanding and interpretation of study findings.  
 
There are, however, limitations to these three clinic-based studies that should be taken into 
consideration. The precision of estimates generated in the analyses of these studies was 
limited by small sample size and limited person time for follow-up. The study findings 
should, therefore, be confirmed by completion of further studies with increased recruitment 
and follow-up periods. Study validity was also reduced by missing data in reported data 
fields or non-availability of data for key outcomes. For example, in the attrition paper 
(chapter 4) there was apparent systematic under-recording of death in Tier.net and no 
available data from other sources, such as hospital records and death registries, to confirm 
vital status amongst individuals experiencing attrition. For the TB paper (chapter 5), in the 
absence of accurate recording of individuals diagnosed with TB, but not started on TB 
treatment in ETR.net, starting TB treatment was used as a proxy to define an incident TB 
case. Furthermore, the effect of IPT exposure was not analysed in the TB study due to 
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significant under-reporting of IPT exposure in ETR.net. IPT is a potential confounder in the 
relationship between baseline CD4 count and incident TB, and the availability of IPT data 
would have greatly strengthened the analysis. The validity of the renal paper (chapter 6) 
was similarly reduced by high rates of missing baseline EGFR and on ART EGFR results. While 
a systematic review of healthcare records from individuals with missing EGFR results was 
completed, this process was hampered by difficulties in locating records and accurately 
finding the EGFR results within records that were successfully accessed.  
 
Although HIV-positive individuals starting ART at the three DOH Arm A clinics were managed 
according to standard DOH ART guidelines, there were some important differences in their 
management to that of the standard care scenario. During the study period, January 2014 to 
May 2016, individuals starting ART outside of pertinent local guidelines signed research 
informed consent. Signing research informed consent, an activity that would not be part of 
standard care, may have affected health-related behaviours such as retention in ART care 
and ART adherence. Furthermore, clinic- and community-based services, during the study 
period, were strengthened for PopART by additional clinic staff, community HIV care 
providers (CHiPs) and PC teams. These additional staff may also have positively impacted 
retention in ART care and ART adherence. In addition there may have been some selection 
biases as a result of this increased clinic and community support. After the introduction of 
PopART activities in January 2014 there was a rapid increase in ART uptake, of up to three 
times as many new ART initiations per month, at the three study clinics. This increase is 
likely to have been partly the result of CHiPs household activities, which may have resulted 
in individuals with certain characteristics linking to care. The baseline characteristics of 
these individuals may be different to those that would be found in a standard care scenario 
without the CHiPs support; this may, in turn, have affected ART outcomes in this cohort and 
limited the generalisability of the research findings. 
 
The provision of ART regardless of CD4 count in this setting, ahead of universal access 
becoming standard care, may have further impacted the study results in several ways. A 
previous study showed that approximately one-third of individuals documented as lost to 
follow-up from ART care, in comparable settings, have in fact transferred to another clinic 
without informing staff (silent transfers). (50) In the context of PopART, this trend may have 
been greater amongst individuals with baseline CD4 counts >500 cells/µL, who, eager to 
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start ART, would have come to the PopART clinic to start ART outside of local guidelines. 
After ART initiation, they may then have returned to their ‘usual’ clinic for ongoing 
treatment and consequently been documented as lost to follow-up. Furthermore, HIV 
treatment narratives in communities including those  in the PopART trial have traditionally 
focused on starting ART when your CD4 count drops to a certain level. (51) This narrative 
made explaining the risks and benefits of routinely starting ART at higher CD4 counts, when 
an individual is more likely to be clinically well, challenging. (51) In this regard, it is possible 
that the lack of community familiarity with the risks and benefits of starting ART at baseline 
CD4 counts >500 cells/µL may have adversely affected retention in ART care in this group. 
Going forward, now that ART regardless of CD4 count is standard care, it is likely that there 
will be further transition of these community narratives about when is the best time to start 
ART. This transition may in turn positively influence retention in ART care amongst 
individuals initiating ART at baseline CD4 counts >500 cells/µL. (51) 
 
8.4 Systematic review and meta-analysis of the association of baseline CD4 
count with ART adherence  
8.4.1 ART adherence systematic review and meta-analysis findings  
This systematic review, which included 28 published research papers, 18 of which were 
included in the meta-analysis, showed lower ART adherence among HIV-positive adults 
starting ART in higher baseline CD4 count categories (pooled OR 0.90; 95% CI 0.84-0.96). 
These baseline CD4 count categories varied between studies; the most common 
comparison, reported by 11 studies, was between individuals with baseline CD4 counts 
above and below 200 cells/µL. Median baseline CD4 counts in the included studies were low 
overall, with only two studies reporting on HIV-positive individuals starting ART at baseline 
CD4 counts >500 cells/µL. In analysis restricted to these two studies, there was no 
difference in ART adherence between individuals with baseline CD4 counts above and below 
500 cells/µL (pooled OR = 1.01; 95% CI 0.97-1.05). 
 
8.4.2 ART adherence systematic review and meta-analysis strengths finding in context  
Published ART adherence levels in high-burden settings are generally low (<60%). (52) Poor 
adherence to ART in these settings is attributed to a wide range of factors, including stock-
outs of ART medication, contrary health beliefs, pill burden and mental health issues. (53) 
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The varied nature of factors associated with poor adherence suggests that multiple 
interventions, addressing a wide range of causal factors, are needed to improve ART 
adherence. (53) Differentiated care models using standardised criteria for identifying 
individuals at high risk of poor adherence for increased support may again be an effective 
strategy for improving adherence to ART. (53) Furthermore, efavirenz (EFV) remains the 
NNTRI of choice for first-line ART in high-burden settings, and neuropsychiatric side effects, 
common in individuals taking EFV, (54) may adversely affect ART adherence. Access to 
alternative ART drugs with lower toxicity, such as dolutegravir (DTG), may be effective in 
improving adherence. (49) DTG is also associated with reduced risk of developing drug 
resistance (HIVDR), which may further improve ART outcomes. (49) Modelling studies 
suggest that rates of HIVDR, particularly to NNRTIs, will increase with universal access to 
ART. (55) This predicted increase in HIVDR further strengthens the argument for improved 
access to DTG in high-burden settings. (55, 56) At the same time, extensive focused research 
is needed to evaluate the potential routine use of parentally administered intermittent ART, 
such as intramuscular cabotegravir and rilpivirine administered every 4 to 8 weeks, to 
improve clinical outcomes with ART. (57)  
 
8.4.3 ART adherence systematic review and meta-analysis strengths and limitations 
This systematic review and meta-analysis evaluated an important topic. The study included 
data on a large number of individuals, more than 72,000 adults, and was rigorously 
completed according to the PRISMA guidelines. (58) However, there were key limitations for 
consideration. The study found the included studies to be of poor quality overall and 
comparison of results across included studies was limited by extensive heterogeneity in the 
methodologies used in different studies. This applied particularly to differences in baseline 
CD4 count categories in studies that reported baseline CD4 count as a categorical variable. 
There was also marked heterogeneity in the definitions of ART non-adherence between 
studies. This definition ranged from <95% self-reported ART adherence over the last three 
days to pharmacy records showing an unscheduled treatment interruption of more than 
three months.  
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8.5 How can the results of this PhD dissertation be used to improve clinical 
care in high-burden settings? 
8.5.1 PhD dissertation results  
There remains a significant HIV treatment gap in high-burden settings. Programme 
implementers in these settings will need to strengthen services at all steps in the HIV 
treatment continuum if they are to reach the 90-90-90 targets and fulfil the promise of 
universal access to ART. (44) The studies presented in this dissertation are some of the first 
to report on provision of household-based HIV POCT and ART regardless of CD4 count, in a 
programmatic setting, and highlight some important benefits of these approaches. These 
include the potential for a reduction in TB incidence and renal dysfunction amongst HIV-
positive individuals when starting ART at CD4 counts >500cell/µL. The studies also identified 
areas of concern, including the need for rigorous HIV POCT QA/QC when conducting 
household-based HIV POCT, increased attrition amongst individuals starting ART at baseline 
CD4 counts >500 cells/µL and a trend toward decreased ART adherence amongst individuals 
starting ART at higher CD4 counts. 
 
8.5.2 Contextual gaps highlighted in completion of the PhD dissertation  
In addition to the study results, through the conduct of the studies included in this 
dissertation, a number of important gaps were identified in the knowledge base, health 
systems, drugs and technologies and approach to the HIV-positive individual used for 
implementation of HIV treatment services. 
 
Research evidence 
There are very limited published data on the outcomes evaluated in this dissertation, and 
further operational studies are urgently needed to confirm these results and address other 
evidence gaps. A further challenge to developing the required strong evidence base, to 
support HIV treatment services, is the marked heterogeneity in operational research 
methodologies and contextual factors between operational research studies. (59) This issue 
was clearly illustrated in the adherence systematic review (chapter 7), and increased efforts 
to standardise operational research methodologies are needed. The WHO has recently 
published guidelines to strengthen and standardise criteria and data collection for the 
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conduct of operational research studies. (59) Improved dissemination of these types of 
guidelines should be a priority. 
 
Health systems 
Effective management of HIV and TB at the PHC level is critical for high-burden settings. (60) 
The number of HIV-positive individuals in these settings continues to increase. At the same 
time there is a steady decline in global HIV and TB funding support, further stretching health 
systems. As described above, differentiated models for integrated HIV and TB care, 
implemented according to context, may be an effective strategy. There is, however, limited 
research evaluating how best to implement these models and their cost-effectiveness.  
 
Health systems challenges at busy PHC clinics are further exacerbated by limitations in 
routine data systems, such as those experienced with the use of Tier.net and ETR.net during 
completion of this dissertation. Further to high rates of missing data, integration of 
individual-level data across different health facilities and between clinic- and community-
based services is severely restricted. (61) This limitation was clearly illustrated in the analysis 
of attrition (chapter 4), where the extent to which silent transfers contributed to attrition 
was not apparent in the routine data, in turn leading to possible under-estimation of the 
actual number of individuals remaining on ART. Loss to follow-up between the time of HIV 
diagnosis and starting ART is often high, (62) and integration of clinic and community 
databases has the potential to improve follow-up of individuals testing HIV-positive in the 
community and not linking to ART care.  
 
Technologies and drugs  
The research presented for this dissertation also highlighted limitations of diagnostic 
technologies and ART regimens currently used by HIV treatment services in high-burden 
settings. There are concerns over the accuracy and acceptability of currently used HIV POCT 
kits; development and field testing of more accurate HIV POCT testing kits and self-testing 
strategies should be a priority. (7) Access to laboratory services in many high-burden 
settings is limited, and increased access to a range of affordable POCT tests, including CD4 
count and viral load testing, may improve HIV treatment outcomes. (63, 64) In areas where 
laboratory services are available, more cost-effective strategies for aspects of laboratory-
based ART monitoring are needed. These strategies may include pooling of viral load, which 
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can reduce the cost of viral load monitoring. (65) As well as the improved use of renal 
dipstick POCT for renal monitoring of individuals taking tenofovir, which can both improve 
access to renal monitoring and reduce cost. (45) Tenofovir and efavirenz, drugs which are 
strongly associated with renal toxicity and neuropsychiatric disturbances respectively, 
remain first-choice ART in high-burden settings. Improved access to newer, alternative ART 
drugs, such as TAF and DTG, may contribute to improved outcomes on ART. (49) However 
there are some uncertainties about their safety and effectiveness for routine use in high-
burden settings that urgently need to be evaluated. (49) This further research needs to be 
combined with strong advocacy across the globe to increase affordable access to newer ART 
drugs in these regions.  
 
Client-centeredness  
As outlined above, wide-ranging biomedical and structural interventions, backed by strong 
evidence, adequate resources, good policy and strong political will are required for the fight 
against HIV and TB in high-burden settings. (66) Ultimately, though, underpinning the 
success of all these interventions are the individuals affected by HIV and TB, and how these 
individuals utilise and experience PHC services. (67) The importance of a client-centred 
approach in the delivery of PHC services has long been recognised, and in 2016, building on 
the PHC principles outlined in Alma-Ata in 1972, (68) the WHO published the ‘Framework on 
integrated people-centred health services’. This framework re-emphasised the critical role 
of the client-centred approach and the need for healthcare providers to incorporate the 
views of individuals, families and communities for the holistic provision of essential health 
services. (67)  
 
8.6 Conclusions 
The number of HIV-positive individuals in high-burden settings continues to increase 
annually across the world. (10) With WHO guidelines now recommending universal access 
to ART, there will be increasing numbers of individuals being tested for HIV, being diagnosed 
HIV-positive and starting ART at higher CD4 counts. The PopART trial has provided an 
excellent opportunity to evaluate key aspects of the provision of community-based HIV 
POCT and ART regardless of CD4 count, in a programmatic context, ahead of these services 
being standard care in high-burden settings. Overall, the studies presented for this PhD 
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dissertation demonstrated both benefits and challenges when conducting household-based 
HIV POCT and routinely starting HIV-positive individuals on ART at CD4 counts >500 cells/µL. 
The findings of these studies need to be consolidated, through integration with findings 
from RCTs and other operational research studies, for the development of a strong evidence 
base to strengthen the delivery of HIV treatment services in high-burden settings.  
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